CN111492066A - Methods of antibody targeting using transcripts and compositions derived therefrom - Google Patents
Methods of antibody targeting using transcripts and compositions derived therefrom Download PDFInfo
- Publication number
- CN111492066A CN111492066A CN201880082663.9A CN201880082663A CN111492066A CN 111492066 A CN111492066 A CN 111492066A CN 201880082663 A CN201880082663 A CN 201880082663A CN 111492066 A CN111492066 A CN 111492066A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- acid sequence
- light chain
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 187
- 239000000203 mixture Substances 0.000 title claims abstract description 177
- 230000008685 targeting Effects 0.000 title description 3
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 364
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 247
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 140
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 132
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 132
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 61
- 201000011510 cancer Diseases 0.000 claims abstract description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 48
- 201000010099 disease Diseases 0.000 claims abstract description 42
- 230000003463 hyperproliferative effect Effects 0.000 claims abstract description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 1107
- 239000012634 fragment Substances 0.000 claims description 292
- 230000027455 binding Effects 0.000 claims description 266
- 239000000427 antigen Substances 0.000 claims description 265
- 108091007433 antigens Proteins 0.000 claims description 265
- 102000036639 antigens Human genes 0.000 claims description 265
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 147
- 210000004027 cell Anatomy 0.000 claims description 114
- 238000012216 screening Methods 0.000 claims description 54
- 230000006870 function Effects 0.000 claims description 33
- 102000039446 nucleic acids Human genes 0.000 claims description 30
- 108020004707 nucleic acids Proteins 0.000 claims description 30
- 239000013598 vector Substances 0.000 claims description 29
- 108091008875 B cell receptors Proteins 0.000 claims description 28
- 230000008707 rearrangement Effects 0.000 claims description 19
- 238000004590 computer program Methods 0.000 claims description 17
- 210000004072 lung Anatomy 0.000 claims description 14
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 13
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 13
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 13
- 208000005017 glioblastoma Diseases 0.000 claims description 13
- 230000003053 immunization Effects 0.000 claims description 13
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 13
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 13
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 12
- 230000001413 cellular effect Effects 0.000 claims description 12
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 11
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 11
- 208000030173 low grade glioma Diseases 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 10
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 210000004962 mammalian cell Anatomy 0.000 claims description 8
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 7
- 238000003860 storage Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 210000004102 animal cell Anatomy 0.000 claims description 5
- 230000002538 fungal effect Effects 0.000 claims description 5
- 241000238631 Hexapoda Species 0.000 claims description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 210000005253 yeast cell Anatomy 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 241000271566 Aves Species 0.000 claims description 2
- 210000001938 protoplast Anatomy 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 abstract description 7
- 210000001519 tissue Anatomy 0.000 description 242
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 231
- 239000000523 sample Substances 0.000 description 97
- 108090000623 proteins and genes Proteins 0.000 description 84
- 235000001014 amino acid Nutrition 0.000 description 70
- 102000004169 proteins and genes Human genes 0.000 description 63
- 235000018102 proteins Nutrition 0.000 description 61
- 150000001413 amino acids Chemical class 0.000 description 58
- 229940024606 amino acid Drugs 0.000 description 57
- 108090000765 processed proteins & peptides Proteins 0.000 description 42
- 108060003951 Immunoglobulin Proteins 0.000 description 39
- 102000018358 immunoglobulin Human genes 0.000 description 39
- 102000004196 processed proteins & peptides Human genes 0.000 description 35
- 235000002639 sodium chloride Nutrition 0.000 description 35
- 229920001184 polypeptide Polymers 0.000 description 33
- 230000013595 glycosylation Effects 0.000 description 28
- 238000006467 substitution reaction Methods 0.000 description 27
- 238000006206 glycosylation reaction Methods 0.000 description 26
- 150000003839 salts Chemical class 0.000 description 26
- 239000003814 drug Substances 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 20
- 102000053602 DNA Human genes 0.000 description 20
- 210000004100 adrenal gland Anatomy 0.000 description 20
- 230000000069 prophylactic effect Effects 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 229940124597 therapeutic agent Drugs 0.000 description 19
- -1 phosphoryl groups Chemical group 0.000 description 18
- 210000001685 thyroid gland Anatomy 0.000 description 18
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 125000000539 amino acid group Chemical group 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 13
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 241000288906 Primates Species 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000004071 biological effect Effects 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 230000009260 cross reactivity Effects 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000013270 controlled release Methods 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 7
- 238000003559 RNA-seq method Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 210000004602 germ cell Anatomy 0.000 description 7
- 238000010166 immunofluorescence Methods 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 150000001720 carbohydrates Chemical group 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000002864 sequence alignment Methods 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 108091035707 Consensus sequence Proteins 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000007975 buffered saline Substances 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 125000003147 glycosyl group Chemical group 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000003259 recombinant expression Methods 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000009824 affinity maturation Effects 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000007951 isotonicity adjuster Substances 0.000 description 4
- 239000008176 lyophilized powder Substances 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 229950008882 polysorbate Drugs 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 201000010153 skin papilloma Diseases 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 108091029865 Exogenous DNA Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 102000025171 antigen binding proteins Human genes 0.000 description 3
- 108091000831 antigen binding proteins Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000013626 chemical specie Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 239000002577 cryoprotective agent Substances 0.000 description 3
- 208000030381 cutaneous melanoma Diseases 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 102000035122 glycosylated proteins Human genes 0.000 description 3
- 108091005608 glycosylated proteins Proteins 0.000 description 3
- 229960002885 histidine Drugs 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 230000037439 somatic mutation Effects 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 2
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108700034637 EC 3.2.-.- Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 2
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 244000292604 Salvia columbariae Species 0.000 description 2
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 2
- 235000001498 Salvia hispanica Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 208000033133 Testicular seminomatous germ cell tumor Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000003070 absorption delaying agent Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 235000014167 chia Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical group C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 2
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000002818 protein evolution Methods 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000012383 pulmonary drug delivery Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000003708 skin melanoma Diseases 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 208000024662 testicular seminoma Diseases 0.000 description 2
- 239000006208 topical dosage form Substances 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
- PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
- RXXCIBALSKQCAE-UHFFFAOYSA-N 3-methylbutoxymethylbenzene Chemical compound CC(C)CCOCC1=CC=CC=C1 RXXCIBALSKQCAE-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241001299703 Azara integrifolia Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000188156 Tamu Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000003103 bodily secretion Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- OKOHFSWRKRCHAD-UHFFFAOYSA-N ethane ethanesulfonic acid Chemical compound CC.CCS(O)(=O)=O OKOHFSWRKRCHAD-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229960004887 ferric hydroxide Drugs 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000000893 fibroproliferative effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005649 metathesis reaction Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000014371 penile sarcoma Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present disclosure relates to a method of identifying and generating antibody-based cancer therapies. In some embodiments, methods are directed to identifying nucleic acid sequences encoding antibodies or antibody fragments from transcriptome or genomic DNA sequences of a sample. Another embodiment of the disclosure is a computer-implemented method of detecting the presence of a nucleic acid sequence encoding an antibody or antibody fragment in a transcriptome of a sample. The present disclosure also provides compositions comprising an antibody or antibody fragment, wherein the antibody or antibody fragment reacts with cancer tissue. The present disclosure also relates to methods of treating a subject diagnosed with or suspected of having a hyperproliferative disease, comprising administering to the subject any one or combination of the pharmaceutical compositions disclosed herein.
Description
Cross Reference to Related Applications
This application claims the benefit of priority from U.S. provisional patent application No. 62/575,369 filed on 2017, 10, 20, the disclosure of which is incorporated herein by reference.
Background
The generation of specific antibodies for cancer therapy is a major task involving a lengthy process of antigen identification, immunization, hybridoma production, and in most cases antibody humanization. There remains a need in the art for methods of identifying and generating antibodies for cancer therapy.
Disclosure of Invention
The present invention relates to a method for identifying and producing antibody-based cancer therapies. In some embodiments, the method of identifying a nucleic acid sequence encoding an antibody or antibody fragment from a transcriptome or genomic DNA sequence of a sample comprises the steps of:
a. screening the transcriptome or genomic DNA sequences of the sample for enriched nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences;
b. calculating a clonality score for the sample;
c. the nucleic acid sequences are divided into the first set of nucleic acid sequences and the second set of nucleic acid sequences according to a sequence alignment.
Optionally, after the classifying step, the method may further include the steps of: (d) identifying from the first set of nucleic acid sequences a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable strand. It will be appreciated that the steps of identifying a nucleic acid sequence encoding at least one CDR of the variable chain and editing the plurality of CDR sequences may be repeated one or more times.
In other aspects of the methods disclosed herein, an exemplary method may comprise the steps of:
e. screening the transcriptomes of a series of control subjects for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences;
f. calculating a clonality score for the sample;
g. identifying the most enriched CDR3 sequence from the sample or series of samples; and
h. obtaining a set of abundantly expressed nucleic acid sequences encoding antibody fragments from the series of control subjects, and comparing the nucleic acid sequences of the first set from the series of control subjects with the nucleic acid sequences of the first set from the subjects.
Steps (e) to (h) are carried out before, simultaneously with or after steps (a) to (c). Preferably, said step of identifying from the subject's transcriptome a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable strand is based on said step of comparing sets of abundantly expressed nucleic acid sequences from step (h).
The first set of abundantly expressed nucleic acid sequences from the subject encodes one or a combination of antibody fragments. Suitable antibody fragments include: an Fc portion of an antibody, a single chain variable fragment of an antibody (ScFv), an Fv portion of an antibody, an Fab fragment of an antibody, an F (ab')2 fragment of an antibody, an Fd fragment of an antibody, an IgG-like fragment of an antibody, a variable chain of an antibody, and/or a constant region of an antibody. In other aspects of the first set of abundantly expressed nucleic acid sequences from the subject, the nucleic acid sequences encode a variable heavy chain and/or variable light chain portion of the antibody.
In other embodiments, the screening step comprises screening for nucleic acid sequences encoding antibody fragments of one or more B Cell Receptor (BCR) sequences, and the step of calculating a clonality score for an antibody is determined, at least in part, by the following equation:
where Ci is the clone score of rearrangement i and N is the total number of rearrangements. Exemplary screening methods include performing FASTQ, MIXCR, and/or VDJtools functions on the transcriptome data.
Advantageously, prior to screening the transcriptome of the subject for nucleic acid sequences encoding one or more antibody fragments, aligning the amino acid sequences comprises performing an alignment of cloned sequences. One non-limiting example of a function that aligns cloned sequences includes performing an immunization SEQ function.
The sample used in the disclosed methods is a tissue sample from a subject having a hyperproliferative cellular disease. Samples that may be considered include, but are not limited to, cancer tissue from: glioblastoma multiforme, low-grade gliomas, lung adenocarcinomas, lung squamous carcinomas, pancreatic adenocarcinomas and skin cancers.
Another embodiment of the invention is a computer-implemented method for detecting the presence of a nucleic acid sequence encoding an antibody or antibody fragment in a transcriptome of a sample, the method comprising: at least one processor and memory are included in the system.
a. Screening, by the at least one processor, the transcriptome of the subject for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences;
b. calculating, by the at least one processor, a clonality score;
c. separating, by the at least one processor, the nucleic acid sequences into the first set of nucleic acid sequences and the second set of nucleic acid sequences according to the clonality score.
The at least one processor may be further configured to (d) identify a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable strand from the first set of nucleic acid sequences after performing the step of classifying. The processor may repeat the steps of identifying a nucleic acid sequence encoding at least one CDR of the variable chain and editing the plurality of CDR sequences one or more times.
The methods disclosed herein may further comprise the steps of:
e. screening the transcriptomes of a series of control subjects for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences;
f. calculating a clonality score corresponding to one or more of the nucleic acid sequences in each of the first and second sets of nucleic acid sequences;
g. dividing the nucleic acid sequences into the first set of nucleic acid sequences and the second set of nucleic acid sequences based on the clonality score; and
h. obtaining a set of abundantly expressed nucleic acid sequences encoding antibody fragments from the series of control subjects, and comparing the nucleic acid sequences of the first set from the series of control subjects with the nucleic acid sequences of the first set from the subjects.
Steps (e) to (h) are carried out before, simultaneously with or after steps (a) to (c). Said step of identifying from the subject's transcriptome a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable strand is based on said step of comparing sets of abundantly expressed nucleic acid sequences from step (h).
In other embodiments, the first set of abundantly expressed nucleic acid sequences from the subject encodes one or a combination of antibody fragments selected from: an Fc portion of an antibody, a single chain variable fragment of an antibody (ScFv), an Fv portion of an antibody, an Fab fragment of an antibody, an F (ab')2 fragment of an antibody, an Fd fragment of an antibody, an IgG-like fragment of an antibody, a variable chain of an antibody, and a constant region of an antibody.
In other embodiments, the first set of abundantly expressed nucleic acid sequences from the subject encodes one or a combination of variable heavy and/or variable light chain portions of the antibody.
In other embodiments, the screening step comprises screening for nucleic acid sequences encoding antibody fragments of one or more B Cell Receptor (BCR) sequences, and the step of calculating a clonality score for the sample is determined, at least in part, by the equation:
wherein Ci is the clone score of rearrangement i and N is the total number of rearrangements; and wherein said classifying nucleic acids into said first set of nucleic acid sequences is performed if said score is 0.1 or higher.
In other embodiments, the screening the transcriptome of the series of samples for nucleic acid sequences encoding one or more antibody fragments comprises performing FASTQ, MIXCR, and vdjsols functions on the transcriptome data. Screening the transcriptome of the subject for nucleic acid sequences encoding one or more antibody fragments comprises performing an alignment of cloned sequences. Alignment of cloned sequences includes performing an immunization SEQ function.
Samples contemplated include tissue samples from subjects with hyperproliferative cellular diseases, such as: glioblastoma multiforme, low-grade gliomas, lung adenocarcinomas, lung squamous carcinomas, pancreatic adenocarcinomas and skin cancers.
In another embodiment, the first set of nucleic acids encoding antibodies or antibody fragments encodes antibodies capable of binding to one or more cells from the sample and/or subject.
The invention also features a method of editing a set of nucleic acid sequences encoding an antibody or antibody fragment from a sample, the method comprising:
(a) obtaining at least one nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of a variable strand from a transcriptome of the subject by the method of any one of claims 1 to 25; and
(b) repeating step (a) until a plurality of nucleic acid sequences encoding the antibody or antibody fragment are aggregated from the sample.
In other embodiments, a method of designing an antibody or antibody fragment capable of binding a cellular epitope from a sample comprises:
(a) obtaining at least one nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of a variable strand from a transcriptome of the subject by the method of any one of claims 1 to 25;
(b) repeating step (a) until a plurality of nucleic acid sequences encoding the antibody or antibody fragment are aggregated from the sample;
(c) cloning one or more nucleic acids in a vector or synthesizing the antibody by solid state chemical synthesis; and if the one or more nucleic acid sequences are cloned into a vector, (d) converting the vector into a host cell, and (e) allowing sufficient time for the recombinant production of the encoded antibody or antibody fragment by the host cell.
In other embodiments, a composition comprising an antibody or antibody fragment, the composition comprising at least one CDR sequence obtained by performing any one of the methods described above.
In other embodiments, an antibody library comprising at least one amino acid sequence obtained by performing any of the above methods.
In other embodiments, a non-transitory computer program product encoded on a computer-readable storage medium, the non-transitory computer program product comprising instructions for:
a. screening the transcriptome of the subject for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences;
b. calculating a clonality score corresponding to one or more of the nucleic acid sequences in each of the first and second sets of nucleic acid sequences;
c. separating the nucleic acid sequences into the first set of nucleic acid sequences and the second set of nucleic acid sequences based on the clonality score.
Optionally, the non-transitory computer program product of claim 30 further comprising instructions for: (d) after performing the step of classifying, identifying from the first set of nucleic acid sequences a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable strand. Preferably, instructions are included for repeating the steps of identifying a nucleic acid sequence encoding at least one CDR of the variable chain and editing the plurality of CDR sequences.
The inventors also consider instructions for the following steps:
e. screening the transcriptomes of a series of control subjects for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences;
f. calculating a clonality score corresponding to one or more of the nucleic acid sequences in each of the first and second sets of nucleic acid sequences;
g. dividing the nucleic acid sequences into the first set of nucleic acid sequences and the second set of nucleic acid sequences based on the clonality score; and
h. obtaining a set of abundantly expressed nucleic acid sequences encoding antibody fragments from the series of control subjects, and comparing the nucleic acid sequences of the first set from the series of control subjects with the nucleic acid sequences of the first set from the subjects.
Steps (e) to (h) are carried out before, simultaneously with or after steps (a) to (c). Said step of identifying from the subject's transcriptome a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable strand is based on said step of comparing sets of abundantly expressed nucleic acid sequences from step (h).
The first set of abundantly expressed nucleic acid sequences from the subject encodes one or a combination of antibody fragments selected from: an Fc portion of an antibody, a single chain variable fragment of an antibody (ScFv), an Fv portion of an antibody, an Fab fragment of an antibody, an F (ab')2 fragment of an antibody, an Fd fragment of an antibody, an IgG-like fragment of an antibody, a variable chain of an antibody, and a constant region of an antibody.
The first set of abundantly expressed nucleic acid sequences from the subject encodes one or a combination of variable heavy and/or variable light chain portions of the antibody.
The screening step comprises screening for nucleic acid sequences encoding antibody fragments of one or more B Cell Receptor (BCR) sequences, and the step of calculating a clonality score for the antibody is determined, at least in part, by the equation:
where Ci is the clone score of rearrangement i and N is the total number of rearrangements.
The screening of nucleic acid sequences encoding one or more antibody fragments in the transcriptome of a series of control subjects comprises performing FASTQ, MIXCR, and VDJtools functions on the transcriptome data.
Screening the subject's transcriptome for nucleic acid sequences encoding one or more antibody fragments comprises performing an alignment of cloned sequences. The alignment of the cloned sequences comprises performing an immunizing SEQ function.
The sample is a tissue sample from a subject having a hyperproliferative cellular disease, such as cancer tissue selected from the following cancers: glioblastoma multiforme, low-grade gliomas, lung adenocarcinomas, lung squamous carcinomas, pancreatic adenocarcinomas and skin cancers.
In other embodiments, the method of verifying antibody specificity uses immunofluorescence methods known in the art by comparing antibody binding to cancer and normal tissue.
In other embodiments, the composition of antibodies is broadly reactive against cancer tissue, but rarely against normal tissue. In a preferred embodiment, the composition of cancer specific antibodies has the amino acid sequence identified in sequence ID 1-9.
In other embodiments, the composition of antibodies has a narrow specificity for the tissue from which the antibody sequence was synthesized from the immune sequence data.
In other embodiments, the composition of individual cancer-specific antibodies of claim 45 has the amino acid sequence identified in sequence ID 10-18.
In other embodiments, the immune sequence-derived high abundance antibody sequences include CDR1, CDR2 and CDR3, as well as somatic mutated sequences. For example, the immune sequence-derived high abundance antibody sequence includes one of the sequences in sequence ID 19.
In other embodiments, the use of an antibody constructed from the sequence of claims 42 to 48 in cancer diagnosis, comprising immunohistochemical staining of tissue by immunofluorescence. The use is contemplated for cancer treatment. The disclosed uses include: antibodies and/or antibody-drug conjugates modified for optimal antibody-dependent cellular cytotoxicity or antibody-dependent phagocytosis. The antibodies are useful as components of bispecific antibodies. The antibodies are used as key components of chimeric antigen receptor T Cells (CART). Other aspects of the invention are described in the detailed description.
In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2206; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2208; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2210; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO 2216; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2218; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO 2220. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO. 2226; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence as set forth in SEQ ID NO. 2228; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2230; a light chain CDR1, said light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2236; a light chain CDR2, said light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2238; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2240. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2246; heavy chain CDR2, said heavy chain CDR2 comprises an amino acid sequence set forth in SEQ ID NO: 2248; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO 2250; a light chain CDR1, said light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO 2256; a light chain CDR2, said light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO 2258; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2260. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2266; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2268; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown as SEQ ID NO: 2270; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2276; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2278; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO 2280. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO. 2286; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO 2288; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO. 2290; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2296; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO 2298; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2300. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2306; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2308; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2310; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2316; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2318; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2320. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2326; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2328; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2330; a light chain CDR1, said light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2336; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2338; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2340. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence as set forth in SEQ ID NO: 2346; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence as set forth in SEQ ID NO: 2348; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 2350; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2356; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2358; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2360. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2366; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2368; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2370; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2376; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2378; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2380. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2386; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2388; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2390; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2396; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2398; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO 2400. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising the amino acid sequence shown in SEQ ID NO: 2406; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2408; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2410; a light chain CDR1, said light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2416; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2418; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO. 2420. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2426; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2428; a heavy chain CDR3, the heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2430; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2436; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2438; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2440. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, the heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2446; a heavy chain CDR2, the heavy chain CDR2 comprising an amino acid sequence as set forth in SEQ ID NO: 2448; a heavy chain CDR3, said heavy chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2450; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2456; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2458; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2460. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, the heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2466; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2468; a heavy chain CDR3, the heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2470; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2476; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2478; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2480. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, the heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2486; a heavy chain CDR2, the heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2488; a heavy chain CDR3, the heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2490; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2496; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2498; and a light chain CDR3, the light chain CDR3 including the amino acid sequence set forth in SEQ ID NO: 2500. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2506; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2508; a heavy chain CDR3, wherein the heavy chain CDR3 comprises an amino acid sequence shown as SEQ ID NO: 2510; a light chain CDR1, said light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2516; a light chain CDR2, said light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2518; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2520. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence as shown in SEQ ID NO: 2526; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence as shown in SEQ ID NO: 2528; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2530; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2536; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2538; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2540. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2546; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2548; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2550; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2556; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2558; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2560. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2566; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2568; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2570; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2576; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2578; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2580. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2586; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2588; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2590; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2596; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2598; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2600. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2606; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2608; a heavy chain CDR3, said heavy chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2610; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2616; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2618; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2620. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence as set forth in SEQ ID NO: 2626; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2628; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2630; a light chain CDR1, the light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2636; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2638; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2640. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2646; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2648; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2650; a light chain CDR1, the light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2656; a light chain CDR2, the light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2658; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2660. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2666; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence shown in SEQ ID NO: 2668; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2670; a light chain CDR1, the light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2676; a light chain CDR2, the light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2678; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2680. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2686; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2688; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2690; a light chain CDR1, the light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2696; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2698; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2700. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2706; heavy chain CDR2, said heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 2708; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence as shown in SEQ ID NO: 2710; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2716; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2718; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO 2720.
In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2204 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2204, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2214 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2214. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2224 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2224, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2234 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2234. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO 2244 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2244, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO 2254 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2254. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO 2264 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2264, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO 2274 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2274. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence set forth as SEQ ID NO. 2284 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO. 2284, and/or a light chain variable domain comprising the amino acid sequence set forth as SEQ ID NO. 2294 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO. 2294. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2304 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2304, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2314 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2314. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2324 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2324, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2334 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2334. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2344 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2344, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2354 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2354. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2364 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2364, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2374 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2374. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2384 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2384, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2394 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2394. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2404 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2404, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2414 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2414. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2424 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2424, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2434 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2434. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2444 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2444, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2454 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2454. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2464 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2464, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2474 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2474. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2484 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2484, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2494 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2494. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising an amino acid sequence as set forth in SEQ ID NO. 2504 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2504, and/or a light chain variable domain comprising an amino acid sequence as set forth in SEQ ID NO. 2514 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2514. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2524 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2524, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2534 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2534. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2544 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2544, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2554 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2554. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2564 or a sequence at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO. 2564, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2574 or a sequence at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO. 2574. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2584 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2584, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2594 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2594. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2604 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2604, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2614 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2614. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2624 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2624, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2634 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2634. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2644 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2644, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2654 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2654. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2664 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2664, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2674 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2674. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2684 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2684, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2694 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2694. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2704 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2704, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2714 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2714.
In another embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2202 or a sequence at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:2202, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2212 or a sequence at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 2212. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2222 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2222, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO. 2232 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2232. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO 2242 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2242, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO 2252 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2252. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO 2262 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2262, and/or a light chain comprising the amino acid sequence as set forth in SEQ ID NO 2272 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2272. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO. 2282 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2282, and/or a light chain comprising the amino acid sequence as set forth in SEQ ID NO. 2292 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2292. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2302 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2302, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO. 2312 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2312. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2322 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2322, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2332 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2332. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2342 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2342 and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2352 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2352. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO:2362 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2362, and/or a light chain comprising the amino acid sequence as set forth in SEQ ID NO:2372 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2372. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO:2382 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2382, and/or a light chain comprising the amino acid sequence as set forth in SEQ ID NO:2392 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2392. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO 2402 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2402, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO 2412 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2412. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID No. 2422 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID No. 2422, and/or a light chain comprising the amino acid sequence shown as SEQ ID No. 2432 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID No. 2432. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2442 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2442, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2452 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2452. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2462 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2462, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2472 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2472. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2482 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2482, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2492 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2492. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2502 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2502, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO. 2512 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2512. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2522 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2522, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO. 2532 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2532. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2542 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2542, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO. 2552 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2552. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2562 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2562, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO. 2572 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2572. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2582 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2582, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO. 2592 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2592. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2602 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2602, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2612 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2612. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2622 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2622 and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2632 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2632. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2642 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2642, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2652 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2652. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2662 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2662, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2672 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2672. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2682 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2682, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2692 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2692. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO 2702 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2702, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO 2712 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2712.
In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO 2202 and the light chain comprises the amino acid sequence set forth in SEQ ID NO 2212. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO. 2222 and the light chain comprises the amino acid sequence set forth in SEQ ID NO. 2232. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2242 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 2252. In certain embodiments, the heavy chain comprises the amino acid sequence set forth as SEQ ID NO:2262 and the light chain comprises the amino acid sequence set forth as SEQ ID NO: 2272. In certain embodiments, the heavy chain comprises the amino acid sequence set forth as SEQ ID NO. 2282 and the light chain comprises the amino acid sequence set forth as SEQ ID NO. 2292. In certain embodiments, the heavy chain comprises the amino acid sequence shown as SEQ ID NO 2302 and the light chain comprises the amino acid sequence shown as SEQ ID NO 2312. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO 2322 and the light chain comprises the amino acid sequence set forth in SEQ ID NO 2332. In certain embodiments, the heavy chain comprises the amino acid sequence shown as SEQ ID NO:2342 and the light chain comprises the amino acid sequence shown as SEQ ID NO: 2352. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2362 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 2372. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2382 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 2392. In certain embodiments, the heavy chain comprises the amino acid sequence shown as SEQ ID NO 2402 and the light chain comprises the amino acid sequence shown as SEQ ID NO 2412. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2422 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 2432. In certain embodiments, the heavy chain comprises the amino acid sequence set forth as SEQ ID NO:2442 and the light chain comprises the amino acid sequence set forth as SEQ ID NO: 2452. In certain embodiments, the heavy chain comprises the amino acid sequence set forth as SEQ ID NO:2462 and the light chain comprises the amino acid sequence set forth as SEQ ID NO: 2472. In certain embodiments, the heavy chain comprises the amino acid sequence set forth as SEQ ID NO:2482 and the light chain comprises the amino acid sequence set forth as SEQ ID NO: 2492. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO 2502 and the light chain comprises the amino acid sequence set forth in SEQ ID NO 2512. In certain embodiments, the heavy chain comprises the amino acid sequence shown as SEQ ID NO:2522 and the light chain comprises the amino acid sequence shown as SEQ ID NO: 2532. In certain embodiments, the heavy chain comprises the amino acid sequence set forth as SEQ ID NO:2542 and the light chain comprises the amino acid sequence set forth as SEQ ID NO: 2552. In certain embodiments, the heavy chain comprises the amino acid sequence shown as SEQ ID NO 2562 and the light chain comprises the amino acid sequence shown as SEQ ID NO 2572. In certain embodiments, the heavy chain comprises the amino acid sequence shown as SEQ ID NO 2582 and the light chain comprises the amino acid sequence shown as SEQ ID NO 2592. In certain embodiments, the heavy chain comprises the amino acid sequence set forth as SEQ ID NO:2602 and the light chain comprises the amino acid sequence set forth as SEQ ID NO: 2612. In certain embodiments, the heavy chain comprises the amino acid sequence set forth as SEQ ID NO:2622 and the light chain comprises the amino acid sequence set forth as SEQ ID NO: 2632. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2642 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 2652. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2662 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 2672. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2682 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 2692. In certain embodiments, the heavy chain comprises the amino acid sequence shown as SEQ ID NO 2702 and the light chain comprises the amino acid sequence shown as SEQ ID NO 2712.
In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2202. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2212. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2222. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2232. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2242. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2252. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2262. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2272. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ id No. 2282. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2292. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2302. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2312. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2322. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2332. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2342. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2352. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2362. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ id No. 2372. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2382. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2392. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2402. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2412. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2422. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2432. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2442. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2452. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ id no: 2462. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2482. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2492. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2502. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2512. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2522. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2532. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2542. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2552. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2562. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ id No. 2572. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2582. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2592. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence that includes 2602. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2612. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2622. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2632. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2642. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2652. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2662. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2672. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2682. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2692. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2702. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2712.
In one embodiment, the antibody or antigen binding fragment thereof is selected from the group consisting of Fab, Fab ', F (ab')2, Fv, domain antibodies, and single chain antibodies. In another embodiment, the antibody or antigen-binding fragment thereof is classified as an isotype selected from the group consisting of IgG, IgM, IgD, IgA, and IgE.
In another aspect, an antibody or antigen-binding fragment thereof that binds to tumor tissue competes with an antibody or antigen-binding portion thereof of any of the preceding aspects or embodiments.
In one embodiment, the antibody, or antigen-binding portion thereof, is humanized.
In one embodiment, the antibody or antigen-binding fragment thereof comprises the antibody or antigen-binding fragment thereof of any one of the aspects or embodiments herein, and a pharmaceutically acceptable carrier. In one embodiment, the pharmaceutical composition is lyophilized.
In one embodiment, the invention features an isolated nucleic acid encoding an antibody or antigen-binding fragment thereof described in any of the aspects and embodiments described herein. In one embodiment, a vector comprises the nucleic acid. In another embodiment, a host cell comprises the vector. In another embodiment, the host cell is a prokaryotic cell or a eukaryotic cell. In another embodiment, the eukaryotic cell is a protoplast cell, an animal cell, a plant cell, a fungal cell, a yeast cell, a mammalian cell, an avian cell, or an insect cell. In another embodiment, the mammalian cell is a CHO cell or a COS cell.
Drawings
FIG. 1(A-G) shows the computational framework for estimating and filtering immunoglobulin sequences based on RNAseq data from TCGA databases FIG. 1A is a schematic diagram of detection and selection of rearranged sequences from TCGA cohorts and frozen lung cancer tissues for curated expansion and experimental validation FIG. 1B is a view showing the number of aligned immunoglobulin reads (left) and clonotype counts (right) in different tumor samples FIG. 1C is a view showing CDR3 sequence clonality in different tumor types FIG. 1D is a profile showing the ratio of aligned immunoglobulin transcripts to total RNAse reads in all samples in TCGA L cohorts.A sample (TCGA-L9-A444-01A) has the highest immunoglobulin transcript and is labeled red and selected for further study.A FIG. 1E is a graph showing the score of all immunoglobulin clones from the most abundant sample (TCGA-L9-A444-01A) and is designated as red, and a selection for further study is based on the dot expression of the Japanese arrow and the point of the selected antibody sequence alignment.
FIG. 2(A and B) shows the results of immunofluorescence experiments demonstrating that recombinant antibodies reconstituted from the CDR3 sequences of L UAD patients cross-react with unrelated L USC and L0 UAD tissues FIG. 2A shows the reactivity of CDR 3-based antibodies to unrelated L USC and L UAD tissues, L3 USC (sample 427) is recognized by H8647, H2L 55, H2L, H2L, H2L 88 and H2L 99, while 2L UAD (sample 429) is recognized by H2L, H2L and H2L, FIG. 2B shows H2L and H2L combined with the UAD tissues of 2L and 2L USC, including control of mouse IgG 2L.
Fig. 3(a to D) shows the results of immunofluorescence experiments, which indicate that H2L 7 binds to various malignant tissues, but shows limited binding to normal tissues fig. 3A shows limited binding between H2L 7 and normal tissues fig. 3B shows that H2L 7 shows broad cross-reactivity to various malignant tissues, including colon adenocarcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, ovarian adenocarcinoma, soft tissue giant cell tumor, liver hepatocellular carcinoma, breast infiltrating ductal carcinoma, skin squamous cell carcinoma, testicular seminoma, L UAD and L usc, fig. 3C shows a selective image depicting binding of H2L 7 to lung squamous cell carcinoma, but not to Normal Adjacent Tissues (NAT), although some non-cellular surface binding to normal parotid, normal pancreatic tissue, normal testicular tissue, normal lymph node tissue and normal spleen tissue is observed, but H2L 7 does not respond to most normal tissues fig. 3D is a fee-view of the squamous cell carcinoma binding of H2L 7 to lung and 16/16 and 4/16.
Figure 4(a to C) shows recombinant antibodies derived from L UAD (sample 463) target genomic sequences while L USC (sample 427) shows limited cross-reactivity figure 4A is a table showing selected sequences with annotation information and gene usage for further extensive analysis and experimental validation figure 4B is a view showing recombinant antibodies expressing heavy and light chains from L UAD and L USC samples by transient transfection figure 4C shows the results of immunofluorescence studies where H5L 12 derived from L UAD sample 463 recognizes 2/2L UAD tissue while H6L 13 derived from L USC sample 427 shows very specific binding to L USC tissue from which it was derived.
FIG. 5 shows an antibody library of 13 recombinant antibodies generated by random pairing of 3 heavy and 6 light chains bound to L USC and L UAD tissues, including isotype control of mouse IgG2a k as a control.
Detailed Description
The generation of specific antibodies for cancer therapy is a major task involving a lengthy process of antigen identification, immunization, hybridoma production, and in most cases antibody humanization. Unlike conventional methods, the present disclosure describes rapid large-scale identification of cancer-specific antibodies directly from human cancer tissues by de novo assembly from transcriptome and genomic sequences. The platform described herein greatly reduces the obstacles presented in the development of human anti-cancer antibodies and lays the foundation for cancer therapy using patient-derived, tumor-reactive monoclonal antibodies.
Further areas of applicability of the present disclosure will become apparent from the detailed description provided herein. It should be understood that the detailed description and specific examples, while indicating the preferred embodiment of the disclosure, are intended for purposes of illustration only and are not intended to limit the scope of the disclosure.
I. Definition of
Unless defined otherwise herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by one of ordinary skill in the art. The meaning and scope of terms should be clear, but in the case of any potential ambiguity, the definitions provided herein take precedence over any dictionary or external definition. Furthermore, unless the context requires otherwise, singular terms shall include the plural and plural terms shall include the singular. In the present application, the use of "or" means "and/or" unless stated otherwise. Furthermore, the use of the term "including" as well as other forms, such as "includes" and "included," is non-limiting. Also, terms such as "element" or "component" include elements and components that comprise one unit and elements and components that comprise more than one subunit unless specifically stated otherwise.
Generally, the nomenclature and techniques described herein relating to cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization are well known and commonly employed in the art. Unless otherwise indicated, the methods and techniques disclosed herein are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. Enzymatic reactions and purification techniques were performed according to the manufacturer's instructions, as is commonly done in the art or as described herein. The nomenclature used in connection with analytical chemistry, synthetic organic chemistry, and pharmaceutical and medicinal chemistry, and the laboratory procedures and techniques described herein are those well known and commonly employed in the art. Standard techniques are used for chemical synthesis, chemical analysis, pharmaceutical preparation, formulation, delivery and patient treatment.
Throughout, ranges are used as shorthand for describing each and every value that is within the range. Any value within the range can be selected as the end point value of the range. In addition, the references cited herein are incorporated by reference in their entirety. In the event that a definition in this disclosure conflicts with a definition in a cited reference, the present disclosure controls.
In order to make the present disclosure more comprehensible, selected terms are defined below.
The articles "a" and "an" are used herein to refer to one or more (i.e., to at least one) of the grammatical object of the article. For example, "an element" refers to one element or more than one element, such as a plurality of elements.
The term "including" is used herein to mean and is used interchangeably with the phrase "including but not limited to" or "including but not limited to".
The term "or" is used herein to mean and is used interchangeably with the term "and/or" unless the context clearly dictates otherwise. For example, an amino acid sequence with modified amino acids is understood to include a selection of amino acids with modified side chains, amino acids with modified backbones, and amino acids with modified side chains and modified backbones.
The term "about" as used herein means within the tolerances typical in the art. For example, "about" can be understood as about 2 standard deviations from the mean. According to certain embodiments, "about" means ± 10%, ± 9%, ± 8%, ± 7%, ± 6%, ± 5%, ± 4%, ± 3%, ± 2%, ± 1%, ± 0.9%, ± 0.8%, ± 0.7%, ± 0.6%, ± 0.5%, 0.4%, 0.3%, ± 0.2%, + 0.1%, or + 0.05%. According to certain embodiments, "about" means ± 5%. When "about" is present before a series of numbers or ranges, it is understood that "about" can modify each number in the series or range.
The term "at least" preceding a plurality or series of numbers (e.g., "at least two") is to be understood to include numbers that are adjacent to the term "at least," and all subsequent numbers or integers that may be included in logic are known from the context. When a series of numbers or ranges is preceded by the word "at least," it is understood that each number in the series or range can be modified.
As used herein, "up" of "up to 10" can be understood to mean up to and include 10, i.e., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
Ranges provided herein are to be understood to include all individual integer values and all subranges within the range.
The term "polypeptide" as used herein refers to any polymer chain of amino acids. The terms "peptide" and "protein" are used interchangeably with the term polypeptide, and also refer to a polymer chain of amino acids. The term "polypeptide" encompasses natural or artificial proteins, protein fragments and polypeptide analogs of a protein sequence. The polypeptide may be monomeric or polymeric.
The term "isolated protein" or "isolated polypeptide" is a protein or polypeptide that is substantially free of other proteins of the same species, expressed by cells of a different species, or does not occur in nature due to its source or origin being unrelated to the native component with which it is associated in nature. Thus, a polypeptide that is chemically synthesized or synthesized in a cellular system different from the cell from which it is naturally derived will be "isolated" from its naturally associated components. Proteins can also be rendered substantially free of naturally associated components by isolation using protein purification techniques well known in the art. An example of an isolated polypeptide is an isolated antibody or antigen-binding portion thereof.
The term "recovering" as used herein refers to the process of making a chemical species, such as a polypeptide, substantially free of naturally associated components by separation (e.g., using protein purification techniques well known in the art).
The term "specific binding" or "specific binding" as used herein refers to the interaction of an antibody, protein or peptide with a second chemical species, meaning that the interaction is dependent on the presence of a particular structure (e.g., an antigenic determinant or epitope) on the chemical species; for example, antibodies recognize and bind to specific protein structures, not to general proteins. If the antibody is specific for epitope "A", the presence of a molecule comprising epitope A (or free, unlabeled A) in a reaction comprising label "A" and the antibody will reduce the amount of label A bound to the antibody.
The term "antibody" as used herein broadly refers to any immunoglobulin (Ig) molecule consisting of four polypeptide chains, two heavy (H) chains and two light (L) chains or any functional fragment, mutant, variant or derivative that retains the essential epitope binding characteristics of the Ig molecule.
In full-length antibodies, each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region comprised of three domains CH1, CH2 and CH 3. each light chain is comprised of a light chain variable region (abbreviated herein as L CVR or V L) and a light chain constant region comprised of one domain C L the VH and V L regions can be further subdivided into hypervariable regions, termed Complementarity Determining Regions (CDRs), interspersed with more conserved regions, termed Framework Regions (FRs), each VH and V L is comprised of three CDRs and four FRs arranged in the order from amino to carboxy, FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. the immunoglobulin molecule can be of any type (e.g., IgG, IgM, IgD, IgA, and IgY), any class (e.g., IgG1, IgG 8, IgG 6866, IgG4, IgA 27, and 2) or any subclass 2.
The term "antigen-binding portion" or "antigen-binding fragment" of an antibody as used herein (or simply "antibody portion" or "antibody fragment") refers to one or more fragments of an antibody that retain the ability to specifically bind an antigen it has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody embodiments of such antibodies can also be in bispecific, bispecific or multispecific form, i.e., specifically bind to two or more different antigens examples of binding fragments encompassed within the term "antigen-binding portion" or "antigen-binding fragment" of an antibody include (i) Fab fragments, monovalent fragments consisting of V L, VH, C L and CH1 domains, (ii) F (ab')2Fragments which are bivalent fragments comprising two Fab fragments linked by a disulfide bond of the hinge region, (iii) Fd fragments consisting of the VH and CH1 domains, (iv) Fv fragments consisting of the V L and VH domains of a single arm of an antibody, (V) dAb fragments (Ward et al, (1989) Nature 341:544-546 and Winter et al, PCTpublication WO 90/05144A1, which are incorporated herein by reference), which comprise a single variable domain, and (vi) isolated Complementarity Determining Regions (CDRs). furthermore, although the two domains V L and VH of the Fv fragment are encoded by separate genes, they may be joined by synthetic linkers using recombinant methods, in which V L and VH regions pair to form a monovalent molecule (known as a single chain Fv scFv), see, for example, Bird et al, (1988) Science 426: 423; and Huston et al, (1988) Acad et al, (1988) Nat. 5885. antibodies also include the bivalent antibody fragment of the USA, which binds to the antigen, USA 5879. the other double antibody fragment of the USA antibodyVH and V L domains are expressed on one polypeptide chain, but the linker used is too short to pair between the two domains on the same chain, thereby forcing these domains to pair with the complementary domains of the other chain and creating two antigen binding sites (see, e.g., Holliger, P. et al, (1993) Proc. Natl. Acad. Sci. USA 90:6444-,Antibody Engineering(2001)Springer-Verlag.New York.790pp.(ISBN 3-540-41354-5)。
as used herein, the term "antibody construct" refers to a polypeptide comprising one or more antigen-binding portions of the invention linked to a linker polypeptide or immunoglobulin constant domain. Linker polypeptides comprise two or more amino acid residues joined by peptide bonds and are used to link one or more antigen binding moieties. Such linker polypeptides are known in the art (see, e.g., Holliger, P. et al, (1993) Proc. Natl. Acad. Sci. USA 90: 6444-. An immunoglobulin constant domain refers to a heavy or light chain constant domain. Human IgG heavy and light chain constant domain amino acid sequences are known in the art and are shown below.
As used herein, "isolated antibody" is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities. Isolated antibodies may be cross-reactive with other antigens from other species. In addition, the isolated antibody may be substantially free of other cellular material and/or chemicals.
The term "chimeric antibody" refers to an antibody comprising the variable region sequences of the heavy and light chains of one species and the constant region sequences of another species, e.g., a variable region antibody having murine heavy and light chains linked to human constant regions.
The term "CDR-grafted antibody" refers to an antibody that comprises heavy and light chain variable region sequences from one species, but in which the sequences of one or more CDR regions of VH and/or V L are replaced with CDR sequences from another species, e.g., an antibody having murine heavy and light chain variable regions in which one or more murine CDRs (e.g., CDR3) have been replaced with human CDR sequences.
The terms "Kabat numbering", "Kabat definitions and" Kabat labeling "are used interchangeably herein. These terms, as known in the art, refer to a system of numbering amino acid residues that are more variable (i.e., hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody or antigen-binding portion thereof (Kabat et al, (1971) Ann. NYAcad, Sci.190: 382. 391 and Kabat, E.A. et al (1991) Sequences of Proteins of immunological Interest, Fifth Edition, U.S. department of health and public service, NIH publication No. 91-3242). For the heavy chain variable region, the hypervariable region ranged from amino acid positions 31 to 35 of CDR1, amino acid positions 50 to 65 of CDR2, and amino acid positions 95 to 102 of CDR 3. For the light chain variable region, the hypervariable region ranged from amino acid positions 24 to 34 of CDR1, amino acid positions 50 to 56 of CDR2, and amino acid positions 89 to 97 of CDR 3.
The terms "receptor" and "receptor antibody" as used herein refer to an antibody or nucleic acid sequence that provides or encodes at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% of the amino acid sequence of one or more framework regions. In some embodiments, the term "receptor" refers to an antibody amino acid or nucleic acid sequence that provides or encodes a constant region. In other embodiments, the term "receptor" refers to an antibody amino acid or nucleic acid sequence that provides or encodes one or more framework regions and one or more constant regions. In a particular embodiment, the term "acceptor" refers to a human antibody amino acid or nucleic acid sequence that provides or encodes at least 80% of the amino acid sequence of one or more framework regions, preferably at least 85%, at least 90%, at least 95%, at least 98%, or 100%. According to this embodiment, the receptor may comprise at least 1, at least 2, at least 3, at least 4, at least 5, or at least 10 amino acid residues that are not (are not) present at one or more specific positions of the human antibody. The acceptor framework region and/or acceptor constant region may, for example, be derived or obtained from a germline antibody gene, a mature antibody gene, a functional antibody (e.g., an antibody well known in the art, an antibody under development, or a commercially available antibody).
The term "CDR" as used herein refers to complementarity determining regions within the variable Sequences of antibodies three CDRs in each variable region of the heavy and light chains, respectively designated CDR1, CDR2 and CDRs 3 the term "set of CDRs" as used herein refers to a set of three CDRs present in a single variable region capable of binding antigen, the defined boundaries of these CDRs have been defined differently according to different systems the system described by Kabat (Kabat et al, Sequences of Proteins of immunological Interest (National of Health, Bethesda, Md. (1987) and (1991)) not only provides a clear residue numbering system suitable for any variable region of antibodies but also provides precise residue boundaries defining three CDRs which can be designated as CDRs Chia and congeners (Chia et al, J.mol.196: 1987) and which may be found to have significant overlap with the CDRs of the CDRs 73, or even with the other CDRs found in the same CDR 27 or other CDRs 73, especially CDRs 73, or 78, respectively, although these CDRs may have significant overlap with the same amino acid residues found using the same CDR Sequences as the CDRs in the Kabat designation (see the amino acid Sequences found in the Kabat et al Sequences of the Kabat et al, No. Specification, No. Abbe found by Kabat et al, No. (see No. Abbe used herein) or No. Abbe used in the same or similar methods such as the Sect et al, the Sect et al.
The term "canonical" residues as used herein refers to residues in the CDR or framework that define the structure of a particular canonical CDR, as described by Chothia et al, J.mol.biol.196: 901-; chothia et al, J.mol.biol.227:799(1992), all of which are incorporated herein by reference. According to Chothia et al, key portions of many antibody CDRs have nearly identical peptide backbone confirmation, despite the wide variation in amino acid sequence levels. Each canonical structure specifies a set of peptide backbone torsion angles for essentially a contiguous segment of the amino acid residues that form the loop.
The terms "donor" and "donor antibody" as used herein refer to an antibody that provides one or more CDRs. In a preferred embodiment, the donor antibody is an antibody from a different species than the antibody from which the framework regions were obtained or derived. In the context of humanized antibodies, the term "donor antibody" refers to a non-human antibody that provides one or more CDRs.
The six CDRs (CDR-L1, CDR-L2 and CDR-L3 of the light chain and CDR-H1, CDR-H2 and CDR-H3 of the heavy chain) also divide the framework regions on the light and heavy chains into four subregions on each chain (FR1, FR2, FR3 and FR4), with CDR1 being located between FR1 and FR2, CDR2 being located between FR2 and FR3 and CDR3 being located between FR3 and FR 4. in the absence of designating a particular subregion as FR1, FR2, FR3 or FR4, the framework region (as otherwise indicated) represents the combined variable region within a single naturally occurring immunoglobulin chain and the combined framework regions as represented by one of the four subregions FR., as otherwise indicated, represent the four subregions of the four or more regions of the framework region as herein.
The term "fragment" as used herein is defined as a physically contiguous portion of the primary structure of a biomolecule. In some embodiments, the biomolecule is an antibody or polypeptide sequence that binds to an antigen recognized by an antibody. For an antibody or polypeptide, a fragment may be defined by a contiguous portion of the amino acid sequence of a protein, and may be at least 3 to 5 amino acids, at least 6 to 10 amino acids, at least 11 to 15 amino acids, at least 16 to 24 amino acids, at least 25 to 30 amino acids, at least 30 to 45 amino acids, and up to the full length of the protein minus a few amino acids in length. For polynucleotides, a fragment is defined by a contiguous portion of a polynucleotide nucleic acid sequence and can be at least 9 to 15 nucleotides, at least 15 to 30 nucleotides, at least 31 to 45 nucleotides, at least 46 to 74 nucleotides, at least 75 to 90 nucleotides, and at least 90 to 130 nucleotides. In some embodiments, the fragment of the biomolecule is an immunogenic fragment.
In some embodiments, the term "functional fragment" refers to any portion of a polypeptide or amino acid sequence that is of sufficient length to retain at least a portion of a biological function similar or substantially similar to the wild-type polypeptide or amino acid sequence upon which the fragment is based. If the fragment is a functional fragment of an antibody or antibody-like molecule, the fragment may be immunogenic and thus have binding affinity for one or more antigens. In some embodiments, a functional fragment of an extracellular matrix-related polypeptide is a polypeptide having 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of the polypeptides disclosed in table 1 and is of sufficient length to retain at least partial binding affinity for one or more ligands that bind to the amino acid sequences of tables 1-17 (including tables 2-16). In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in table 1, and has a length of at least about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, or about 100 contiguous amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 50 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 100 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 150 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 200 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 250 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 300 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 350 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 400 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 450 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 500 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 550 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 600 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 650 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 700 amino acids. In some embodiments, the fragment is a fragment of any of the polypeptides disclosed in tables 1 to 17 and has a length of at least about 750 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 800 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 850 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 900 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 950 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 1000 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and has a length of at least about 1050 amino acids. In some embodiments, the fragment is a fragment of any of the amino acid sequences disclosed in tables 1 to 17, and is no longer than the above-described number of substitutions of the amino acids described in this paragraph. In some embodiments, a composition or pharmaceutical composition of the invention comprises any one or more of the conservative substitutions disclosed in table a.
Human heavy and light chain acceptor sequences are known in the art. In one embodiment of the invention, the human heavy and light chain acceptor sequences are selected from the sequences described in the following table.
Heavy chain receptor sequences
Light chain acceptor sequences
The term "germline antibody gene" or "gene segment" as used herein refers to immunoglobulin sequences encoded by non-lymphoid cells that have not undergone a maturation process that results in gene rearrangement and mutation to express a particular immunoglobulin. (see, e.g., Shapiro et al, Crit. Rev. Immunol.22(3):183-200 (2002); Marchalonis et al, Adv Exp Med biol.484:13-30 (2001)).
The term "hyperproliferative diseases" as used herein refers to those diseases and disorders characterized by hyperproliferation of cells or cells that exhibit dysfunction in their growth cycle, in some embodiments, the hyperproliferative diseases are dysplasia or cancer the term "hyperproliferative diseases" refers to a disease characterized by abnormal proliferation, abnormal growth, abnormal aging, abnormal quiescence or abnormal removal of cells in any organism and includes hyperplasia, neoplasia, cancer, fibroproliferative diseases (such as those involving connective tissue and other diseases characterized by fibrosis, including rheumatoid arthritis, insulin dependent diabetes, glomerulonephritis, cirrhosis and scleroderma), smooth muscle proliferative diseases (such as atherosclerosis and restenosis), chronic inflammation and epithelial cell proliferative diseases (such as psoriasis; keratosis; acne; comedogenic lesions; verrucous lesions; warts, such as verrucous warts, plantar warts, condyloma acuminatum and other diseases, such as those characterized by proliferation of epithelial cells, such as those of flat warts, cervical or thyroid, pancreatic gland, renal gland, thyroid, renal gland, thyroid, renal gland, thyroid, renal gland, adrenal gland, thyroid, renal gland, thyroid, renal gland, adrenal gland, renal gland, adrenal gland, thyroid, renal gland, adrenal gland, thyroid, renal gland, adrenal gland, thyroid, renal gland, adrenal gland, renal gland, adrenal gland, renal gland, adrenal gland, thyroid, renal gland, thyroid, adrenal gland, thyroid, adrenal gland, thyroid, renal gland, adrenal gland, thyroid, adrenal gland, thyroid, adrenal gland, renal gland, adrenal gland, thyroid, adrenal gland, renal gland, adrenal gland, renal gland, thyroid, adrenal gland, renal gland, adrenal gland, renal gland, adrenal gland, thyroid, renal gland, adrenal gland, renal gland.
The term "hyperproliferative-associated protein" as used herein refers to a protein associated with a hyperproliferative disease. In some embodiments, the hyperproliferative-associated protein is an antigen with an abnormally functional growth cycle that is expressed on a cell. In some embodiments, the cell having a dysfunctional growth cycle is cancerous. In some embodiments, the hyperproliferative-associated protein is an antigen that is expressed on hyperproliferative cells in higher amounts than normal cells. In some embodiments, the hyperproliferative-associated protein is an antigen that is expressed on hyperproliferative cells but not on normal cells. In some embodiments, the hyperproliferative cells are cells from a cancer patient sample. In some embodiments, the hyperproliferative cells are cells from cancerous tissues or solid tumors. In some embodiments, the cancer is
The term "critical" residues as used herein refers to certain residues within the variable region which have a greater effect on the binding specificity and/or affinity of an antibody, particularly a humanized antibody. Key residues include, but are not limited to, one or more of the following: residues adjacent to the CDRs, potential glycosylation sites (which can be N-or O-glycosylation sites), rare residues, residues capable of interacting with antigen, residues capable of interacting with CDRs, canonical residues, contact residues between the heavy chain variable region and the light chain variable region, residues in the vernier zone, and residues in the region where the Chothia definition of the variable heavy chain CDR1 overlaps with the Kabat definition of the first heavy chain framework.
The term "host cell" as used herein is intended to refer to a cell into which exogenous DNA has been introduced. It is understood that these terms are not intended to refer to particular subject cells, but to the progeny of such cells. Certain modifications may occur in the progeny due to mutation or environmental impact, and such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein. Preferably, the host cell comprises prokaryotic and eukaryotic cells selected from any phylum of living organisms. Eukaryotic cells include protozoan cells, fungi, plant and animal cells. Other examples include cells, but are not limited to, prokaryotic cell lines, e.coli, mammalian cell lines, CHO, HEK 293 and COS, insect cell line Sf9, and fungal cell, Saccharomyces cerevisiae.
Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). enzymatic reactions and purification techniques can be performed according to the manufacturer's instructions, or as is commonly done in the art or as described herein.
The term "humanized antibody" as used herein is an antibody or variant, derivative, analog or fragment thereof which immunospecifically binds to an antigen of interest and comprises a Framework (FR) region having substantially the amino acid sequence of a human antibody and a Complementarity Determining Region (CDR) having substantially the amino acid sequence of a non-human antibody. As used herein, the term "substantially" in the context of CDRs refers to CDRs whose amino acid sequence is at least 80%, preferably at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to a non-human antibody CDR. Humanized antibodies comprise substantially all of at least one and typically two variable domains (Fab, Fab ', F (ab')2, FabC, Fv), in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin (i.e., donor antibody), and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. Preferably, the humanized antibody further comprises at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. In some embodiments, the humanized antibody comprises both the light chain and the variable domain of the heavy chain. The antibody may also include the CH1, hinge, CH2, CH3, and CH4 regions of the heavy chain. In some embodiments, the humanized antibody comprises only a humanized light chain. In some embodiments, the humanized antibody comprises only humanized heavy chains. In particular embodiments, the humanized antibody comprises only the humanized variable domain of the light chain and/or the humanized heavy chain.
Humanized antibodies may be selected from any class of immunoglobulin including IgM, IgG, IgD, IgA, and IgE, and any isotype including, but not limited to, IgG1, IgG2, IgG3, and IgG 4. Humanized antibodies may comprise sequences from more than one type or isotype, and specific constant domains may be selected to optimize desired effector function using techniques well known in the art.
The framework regions and CDR regions of the humanized antibody do not have to correspond exactly to the parental sequences, e.g., the donor antibody CDR or consensus framework can be mutagenized by substituting, inserting, and/or deleting at least one amino acid residue such that the CDR or framework residue at that site is neither identical to the donor antibody nor the framework residue. In a preferred embodiment, however, such mutations are not widely present. Typically, at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% of the humanized antibody residues will correspond to residues of the parent FR and CDR sequences. The term "consensus framework" as used herein refers to framework regions in a consensus immunoglobulin sequence. The term "consensus immunoglobulin sequence" as used herein refers to a sequence formed by the most frequently occurring amino acids (or nucleotides) in a family of related immunoglobulin sequences (see, e.g., Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987)). In the immunoglobulin family, each position in the consensus sequence is occupied by the most frequently occurring amino acid at that position in the family. If two amino acids occur equally, either can be included in the consensus sequence.
As used herein, a "vernier" region refers to a subset of framework residues that can modulate the CDR structure and fine tune the fitness to the antigen, as defined in Foote and Winter, 1992, J.Mol.biol.224:487-499, which are incorporated herein by reference. Vernier zone residues form a layer under the CDRs and may affect the structure of the CDRs and the affinity of the antibody.
The term "epitope" includes any polypeptide determinant capable of specifically binding to an antibody or antigen-binding portion thereof. In certain embodiments, epitope determinants include chemically active surface groups of a molecule (e.g., amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups), and in certain embodiments may have specific three-dimensional structural characteristics and/or specific charge characteristics. In various embodiments, the epitope can be a linear or sequential epitope of the primary structure of the antigen, i.e., a linear sequence of amino acids. Alternatively, in other embodiments, the epitope may be a conformational epitope having a particular three-dimensional shape when the antigen assumes its secondary structure. For example, a conformational epitope may include non-linear, i.e., non-sequence, amino acids of an antigen.
In a particular embodiment, the epitope is a region of an antigen bound by an antibody or antigen-binding portion thereof. In certain embodiments, an antibody or antigen-binding portion thereof is said to specifically bind to an antigen when the antibody or antigen-binding portion thereof preferentially recognizes a target antigen in a complex mixture of proteins and/or macromolecules.
The term "human antibody" as used herein is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the invention may comprise amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-directed mutagenesis in vitro or by somatic mutation in vivo), for example, in the CDRs, specifically in CDR 3. However, the term "human antibody" as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
The term "recombinant human antibody" as used herein is intended to include all human antibodies prepared, expressed, produced or isolated by recombinant means, such as antibodies expressed using recombinant expression vectors transfected into host cells (further described in section II C below), antibodies isolated from recombinant combinatorial human antibody libraries (Hoogenbomom H.R., (1997) TIBTech.15: 62-70; Azzazy H., and Highsmith W.E., (2002) Clin. biochem.35: 425. 445; GaVilondo J.V.and L arick J.W. (2002) BioTechniques 29: 128. 145; Hoogenbomom H. and Chames P. (2000) Immunology Today 21: 371. 378), antibodies isolated from animals transgenic for human immunoglobulin genes (e.g.mice) (see e.g.Tannolor et al, see Taylor et al, SEQ ID NO: L; 35. 378) and antibodies derived from human immunoglobulin genes (see human antibodies) derived from human immunoglobulin genes transgenic animals transgenic human antibodies derived from human immunoglobulin genes (e.g.20, human antibodies) in vivo or from human immunoglobulin genes derived from human antibodies derived from human immunoglobulin genes (SEQ ID NO: 35, 35. Polyporas) and similar sequences found in human antibodies derived from human immunoglobulin genes (SEQ ID NO: 35, such as well as human antibodies) and human antibodies derived from human immunoglobulin genes (SEQ ID No. 35, SEQ ID No. 5, SEQ ID NO. 5, and SEQ ID No. 5, and SEQ ID NO. 5, such human antibodies derived from human antibodies, see, preferably from human antibodies derived from human.
The terms "crystal" and "crystallized" as used herein refer to an antibody or antigen-binding portion thereof that exists in a crystal form. A crystal is a form of a solid state of matter that is different from other forms such as an amorphous solid state or a liquid crystalline state. Crystals are composed of regular, repeating three-dimensional arrays of atoms, ions, molecules (e.g., proteins such as antibodies) or molecular assemblies (e.g., antigen/antibody complexes). These three-dimensional arrays are arranged according to specific mathematical relationships well known in the art. The basic unit or structural unit that repeats in the crystal is called an asymmetric unit. Repeating asymmetric units in an arrangement that conforms to a given, well-defined crystal symmetry provides a "unit cell" of the crystal. The crystal is obtained by repeating the unit cell by regular translation in all three dimensions. See, e.g., Giege, R. and Ducruix, A.Barrett, Crystallization of nucleic Acids and Proteins, a Practical Approach,2nd ea., pp.201-16, Oxford university Press, New York, New York, (1999) "
The term "polynucleotide" as used herein refers to a polymeric form of two or more nucleotides, i.e., ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide. The term includes single-stranded and double-stranded forms of DNA, but is preferably double-stranded DNA.
The term "isolated polynucleotide" as used herein refers to a polynucleotide (e.g., of genomic, cDNA, or synthetic origin, or some combination thereof) that is "isolated polynucleotide" as a result of its origin: which is not related to all or part of a polynucleotide of which an "isolated polynucleotide" is found in nature; operably linked to a naturally unlinked polynucleotide; or not per se, as part of a larger sequence.
The term "vector" as used herein is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid," which refers to a circular double-stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). After introduction into a host cell, other vectors (e.g., non-prevalent mammalian vectors) can be integrated into the genome of the host cell and thereby replicated along with the host genome. In addition, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply "expression vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present invention, "plasmid" and "vector" are used interchangeably as the plasmid is the most commonly used vector situation. However, the invention is intended to include other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.
The term "operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences. Sequences that are "operably linked" include expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or remotely to control the gene of interest. The term "expression control sequence" as used herein refers to polynucleotide sequences necessary to effect expression and processing of coding sequences to which they are ligated. The expression control sequences include: appropriate transcription initiation, termination, promoter and enhancer sequences; effective RNA processing signals, such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequence); sequences that enhance protein stability; and sequences that enhance protein secretion when desired. The nature of such control sequences depends on the host organism; in prokaryotes, such control sequences typically include a promoter, a ribosome binding site, and a transcription termination sequence; in eukaryotes, generally, such control sequences include promoters and transcription termination sequences. The term "control sequences" is intended to include components whose presence is essential for expression and processing, and may also include other components whose presence is advantageous, such as leader sequences and fusion partner sequences. Expression vectors and host cells known in the art, including expression cassettes, vectors, recombinant host cells, and proteolytic methods for recombinant expression of recombinant proteins and proproteins from a single open reading frame, can be used to express and purify the protein constructs of the present disclosure (e.g., WO 2007/014162, which is incorporated herein by reference in its entirety).
As defined herein, "transformation" refers to any process by which foreign DNA enters a host cell. Transformation can occur under natural or artificial conditions using a variety of methods well known in the art. Transformation may rely on any known method of inserting a foreign nucleic acid sequence into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell being transformed and may include, but is not limited to, viral infection, electroporation, lipofection, and particle bombardment. These "transformed" cells include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome. They also include cells that transiently express the inserted DNA or RNA for a limited period of time.
The term "recombinant host cell (or simply" host cell "), as used herein, is intended to refer to a cell into which exogenous DNA has been introduced. It is understood that these terms are not intended to refer to particular subject cells, but to the progeny of such cells. Certain modifications may occur in the progeny due to mutation or environmental impact, and such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein. Preferably, the host cell comprises a prokaryotic and eukaryotic cell selected from any of the kingdoms of life. Preferably, eukaryotic cells include protozoan cells, fungi, plant and animal cells. Most preferably, host cells include, but are not limited to, the prokaryotic cell lines Escherichia coli, the mammalian cell lines CHO, HEK 293 and COS, the insect cell line Sf9, and the fungal cell Saccharomyces cerevisiae.
Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). enzymatic reactions and purification techniques can be performed according to the manufacturer's instructions, or as is commonly done in the art or as described herein.
The term "inhibit" and its various grammatical forms are used to indicate to limit, block or limit the extent or degree of a certain biological event or effect.
The term "effective amount" is used herein to include an amount of an agent (e.g., a multispecific antibody) sufficient to effect treatment of a disease when administered to a patient to treat an infection in a subject (e.g., by reducing, ameliorating, or maintaining one or more symptoms of an existing disease or disease, or a complication associated therewith). The "effective amount" may vary with the drug, the mode of administration, the disease and its severity and with the medical history, age, weight, family history, genetic makeup, stage of the pathological process, type of prior or concomitant therapy (if any), and other individual characteristics of the patient to be treated. An effective amount includes an amount that causes a clinically appropriate change or stabilization of the indicator of the disease or condition. An "effective amount" refers to an amount of a compound, material, or composition described herein effective to achieve a particular biological result, such as, but not limited to, the biological results disclosed, described, or exemplified herein. Such results may include, but are not limited to, effective alleviation of symptoms associated with any of the disease states mentioned herein, as determined by any means appropriate in the art. The effective amount of the composition may depend on a number of variables including, but not limited to, species, breed, size, height, weight, age, general health of the subject, type, mode or mode of formulation or administration, type and/or severity of the particular disease being treated or the desirability of modulating the activity of the molecular pathway induced by the association of the analog with its receptor. Suitable effective amounts can be determined routinely by those skilled in the art using routine optimization techniques, with the skilled and informed judgment of the practitioner and other factors evident to those skilled in the art. An effective amount of an antibody or mutant or variant described herein can provide some or all of the biological activity as compared to the biological activity induced by the wild-type or naturally occurring polypeptide from which the antibody or mutant or variant is derived. A therapeutically effective dose of an antibody or mutant or variant described herein can provide a sustained biochemical or biological effect and/or increased resistance to degradation when placed in solution, as compared to the normal effect observed when a naturally occurring and fully processed translated protein is administered to the same subject.
An "immunoconjugate" is an antibody or multispecific antibody conjugated to one or more heterologous molecules, including but not limited to cytotoxic agents.
The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents cellular function and/or causes cell death or destruction. Cytotoxic agents include, but are not limited to: a radioactive isotope; a growth inhibitor; enzymes and fragments thereof, such as nucleolytic enzymes; (ii) an antibiotic; toxins, such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof.
The term "administering" as used herein means administering or applying. The term "administering" as used herein includes in vivo administration.
The term "linker" refers to a chemical moiety that links one peptide to another, e.g., an antibody to another. Linkers can also be used to link the antibody to a label or solid substrate. The linker may comprise an amino acid. The linker may be a straight or branched, saturated or unsaturated carbon chain. They may also include one or more heteroatoms within the chain.
The term "enrichment" refers to the process of identifying a transcriptome portion that is increased in number or has an increased number of nucleic acid sequences (e.g., RNA sequences). In some embodiments, the term is relative to the number of Ig-like sequences or CDR3 sequences (sequences homologous thereto) in the transcriptome of the sample. In some embodiments, the term is used to modify the number of Ig-like sequences or CDR3 sequences (sequences homologous thereto) in a transcriptome or genomic deoxyribonucleic acid (DNA) of a sample and corresponds to the abundance of nucleic acid sequences in genomic DNA or a transcriptome encoding Ig-like sequences or CDR3 sequences.
The term "pharmaceutical composition" refers to a formulation in a form that allows the biological activity of the active ingredient contained therein to be effective and does not contain other components that have unacceptable toxicity to the subject to which the composition is administered. The pharmaceutical compositions of the present invention may be administered by a variety of methods known in the art. One skilled in the art will appreciate that the route and/or mode of administration will vary depending on the desired result. In order to administer an antibody according to the invention by certain routes of administration, it may be necessary to coat or co-administer the antibody with a material that prevents its inactivation. For example, the antibody can be administered to the subject in a suitable carrier, such as a liposome or diluent. Pharmaceutically acceptable diluents include saline and buffered aqueous solutions.
By "pharmaceutically acceptable carrier" is meant an ingredient of a pharmaceutical formulation that is non-toxic to a subject, except for the active ingredient. Pharmaceutically acceptable carriers include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. In a preferred embodiment, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion).
The pharmaceutical composition according to the present invention may further comprise adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the presence of microorganisms can be ensured by the above-described sterilization procedures as well as by the inclusion of various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, sorbic acid, and the like). It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like in the compositions. In addition, prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
The term "subject" is used throughout the specification to describe an animal that includes one or more compositions comprising one or more antibodies disclosed herein. In some embodiments, the animal is a human. For diagnosing a condition specific to a particular subject, such as a human, the term "patient" is used interchangeably. In some instances of the description of the present invention, the term "patient" will refer to a human patient suffering from a particular disease or disorder. In some embodiments, the subject may be a human suspected of having cancer or identified as at risk for having cancer. In some embodiments, the subject is suspected of having cancer or has been diagnosed with cancer. In some embodiments, the subject may be a human suspected of having cancer or identified as at risk for cancer or a hyperproliferative disease. In some embodiments, the subject may be a mammal. In some embodiments, the subject may be a non-human animal. The term "mammal" includes humans and non-humans, and includes, but is not limited to, humans, non-human primates, canines, felines, murines, bovines, equines, and porcines; as used herein, refers to an animal, such as a mammal, including a primate (e.g., a human, a non-human primate (e.g., monkey and chimpanzee)), a non-primate (e.g., a cow, pig, camel, llama, horse, goat, rabbit, sheep, hamster, guinea pig, cat, dog, rat, mouse, horse, and whale), or a bird (e.g., a duck or goose). In one embodiment, the subject is a human, such as a human treated or evaluated for a hyperproliferative disease or a human having an HIV infection that would benefit from multispecific antibodies of the invention. In some embodiments, the subject is a subject in need thereof, meaning that the subject is in need of the administered treatment.
The term "salt" refers to acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. Examples of such acids and bases are well known to those of ordinary skill in the art. Such acid addition salts are generally pharmaceutically acceptable, although salts of non-pharmaceutically acceptable acids may be used in the preparation and purification of the compounds in question. Salts include those formed from hydrochloric, hydrobromic, sulfuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, maleic, methanesulfonic and benzenesulfonic acids. In some embodiments, a salt of a composition comprising an antibody or antibody-like molecule can be formed by reacting the free base or a salt, enantiomer or racemate thereof with one or more equivalents of an appropriate acid. In some embodiments, a pharmaceutically acceptable salt of the invention refers to a derivative or amino acid sequence that includes at least one basic group or at least one basic group. In some embodiments, pharmaceutically acceptable salts of the presently disclosed compositions include free amino, free guanidino, pyrazinyl, or pyridyl groups that form acid addition salts. In some embodiments, a pharmaceutically acceptable salt of the invention refers to a modified amino acid which is an acid addition salt of the subject compound with, for example, an inorganic acid (such as hydrochloric acid, sulfuric acid or phosphoric acid) and a suitable organic carboxylic or sulfonic acid, for example, an aliphatic mono-or dicarboxylic acid (such as trifluoroacetic acid, acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, fumaric acid, hydroxymaleic acid, malic acid, tartaric acid, citric acid or oxalic acid) or an amino acid (such as arginine or lysine, an aromatic carboxylic acid (such as benzoic acid, 2-phenoxy-benzoic acid, 2-acetoxybenzoic acid, salicylic acid, 4-aminosalicylic acid, an aromatic aliphatic carboxylic acid (such as mandelic acid or cinnamic acid, a heteroaromatic carboxylic acid (such as nicotinic acid or isonicotinic acid, an aliphatic sulfonic acid (such as methane-, ethane-or 2-hydroxyethanesulfonic acid or aromatic sulfonic acid))), for example benzene-, p-toluene-or naphthalene-2-sulfonic acid. When several basic groups are present, mono-or poly-acid addition salts may be formed. The reaction can be carried out in a salt-insoluble solvent or medium or in a salt-soluble solvent (e.g., water, dioxane, ethanol, tetrahydrofuran or diethyl ether or a mixture of solvents), which can be removed by vacuum or freeze-drying. The reaction may also be a metathesis process, or may be carried out on an ion exchange resin. In some embodiments, the salt may be a physiologically tolerable salt for the patient. The salts of the present invention may be found in anhydrous form or in hydrated crystalline form (i.e., completed or crystallized with one or more water molecules). In some embodiments, the composition or pharmaceutical composition comprises a crystalline form or lyophilized form of the antibody, antibody-like molecule, or salt thereof.
The term "treating" includes eliminating, substantially inhibiting, slowing or reversing the progression of a disease, disorder or disorder, substantially alleviating the clinical or aesthetic symptoms of a disorder, substantially preventing the appearance of the clinical or aesthetic symptoms of a disease, disorder or disorder, and preventing harmful or unpleasant symptoms. As used herein, the term "treating" further refers to performing one or more of the following processes: (a) reducing the severity of the disease; (b) limiting the development of symptoms characteristic of the disease being treated; (c) limiting the worsening of symptoms characteristic of the disease being treated; (d) limiting recurrence of the disease in a patient previously suffering from the disease; (e) limiting the recurrence of symptoms in previously symptomatic patients.
The term "potency" as used herein refers to the neutralizing ability, i.e. the IC of an antibody or fragment thereof50Or IC80。
Humanization and primatization means that an antibody can be "humanized" to reduce immunogenicity to a human recipient in the case where the trispecific fusion antibody or the three antibodies forming the trispecific fusion antibody are non-human antibodies. Methods for humanizing non-human antibodies have been described in the art. See, for example, Jones et al, Nature 321:522-525 (1986); riechmann et al, Nature 332:323-327 (1988); verhoeyen et al, Science 239:1534-1536(1988) and U.S. Pat. No.4,816,567. Typically, residues from the variable domains of non-human antibodies are "introduced" into human immunoglobulin molecules, resulting in antibodies in which some hypervariable region residues and possibly some FR residues of the human antibody are substituted by residues from analogous sites in the non-human antibody. It is important to humanize non-human antibodies while maintaining high affinity for the antigen. For this purpose, three-dimensional immunoglobulin models are generally available and are suitable for analyzing proposed humanized sequences, as compared to the parent non-human antibody. Such analysis allows the identification of residues that may be involved in antigen recognition and binding, and thus the rational design of humanized sequences that retain specificity and affinity for the antigen.
In particular embodiments, a trispecific fusion antibody is formed from any fragment or antibody sequence disclosed herein.
Similarly, a "bispecific" or "trispecific" fusion antibody or three antibodies forming a fusion can be "primatized" to reduce immunogenicity to another primate, non-human receptor, such as the rhesus receptor. "introduction" of residues from the variable domain of a donor antibody (e.g., a non-primate antibody or an antibody of a primate species other than the recipient primate) into a non-human primate recipient immunoglobulin molecule results in an antibody in which some hypervariable region residues and possibly some FR residues of the non-human primate antibody are substituted with residues from analogous sites in the donor antibody. Alternatively, primate antibodies are prepared for the desired primate species by using recipient immunoglobulins having non-primate sequences or sequences from different primate species, introducing Fc fragments and/or residues (including in particular framework region residues) from the desired primate into the recipient immunoglobulin.
"affinity maturation" refers to when one or more hypervariable region residues of an antibody can be substituted to select variants having improved biological properties relative to the parent antibody by using affinity maturation, for example using phage or yeast display. For example, the Fab region of an anti-cancer antigen can be mutated at selected several sites based on available structural information to generate all possible amino substitutions at each site. The antibody variants thus produced are displayed in monovalent form from the surface of a phage particle or yeast cell. The displayed variants are then screened for biological activity (e.g., binding affinity).
As used herein, "operably linked" in reference to a gene operably linked to a promoter refers to the linkage of two components such that expression of the gene is under the control of the promoter to which it is spatially linked. The promoter may be located 5 '(upstream) or 3' (downstream) of the gene under its control. The distance between a promoter and a gene may be about the same as the distance between the promoter and the gene it controls in the gene from which it is derived. As is known in the art, variations in this distance can be accommodated without loss of promoter function. When referring to a signal peptide operably linked to a protein, the term refers to a protein having a signal peptide incorporated as part of the protein in such a way that it can act as a signal peptide. When referring to a coding sequence that encodes a signal peptide operably linked to a coding sequence that encodes a protein, the term "coding sequence" refers to a coding sequence arranged such that translation of the coding sequence results in a protein having a portion that can be incorporated into the signal peptide in a manner that functions as a signal peptide.
As used herein, "conservative" amino acid substitutions may be as defined in table A, B or C below. Antibodies, antibody-like molecules, and derivatives, mutants, variants, and salts thereof include those amino acid sequences in which conservative substitutions have been introduced by solid state chemistry and/or recombinant modification of the nucleic acids encoding the amino acid sequences disclosed herein. In some embodiments, the compositions and pharmaceutical compositions of the invention include 1, 2, 3, 4, 5, or more conservative amino acid substitutions. Amino acids can be classified according to physical properties and contributions to secondary and tertiary protein structure. Conservative substitutions are considered in the art to be the substitution of one amino acid for another with similar properties. Exemplary conservative substitutions are shown in table a.
TABLE A-conservative substitutions I
Alternatively, conserved amino acids can be classified according to L ehninger (Biochemistry, Second Edition; Worth Publishers, inc. ny, n.y. (1975), pp.71-77), as shown in table B.
TABLE B conservative substitutions II
Uncharged-polarity
Alternatively, exemplary conservative substitutions are shown in table C.
TABLE C-conservative substitutions III
It will be appreciated that the amino acids disclosed herein are intended to include polypeptides with insertion, deletion or substitution of one or more amino acid residues, truncation or any combination, and modifications other than insertion, deletion or substitution of amino acid residues.
The term "sample" as used herein refers to a biological sample obtained or derived from a source of interest as described herein. In some embodiments, the source of interest comprises an organism, such as an animal or human. In some embodiments, the biological sample comprises a biological tissue or fluid. In some embodiments, the biological sample may be or include bone marrow, blood cells, ascites, tissue or fine needle biopsy samples, cell-containing bodily fluids, free floating nucleic acids, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymph, gynecological fluids, swabs, vaginal swabs, oral swabs, nasal swabs, washing or lavage fluids (such as ductal or bronchoalveolar lavage fluids), aspirates, scrapings, bone marrow specimens, tissue biopsy specimens, surgical specimens, stool, other bodily fluids, secretions and/or excretions and/or cells produced therefrom, and the like. In some embodiments, the biological sample is or includes a bodily fluid. In some embodiments, the sample is a "raw sample" obtained directly from a target source by any suitable means. For example, in some embodiments, the raw biological sample is obtained by: biopsies (e.g., fine needle or tissue biopsies), surgery, collection of bodily fluids (e.g., blood, lymph, stool, etc.), and the like. In some embodiments, as is clear from the context, the term "sample" refers to a preparation obtained by processing (e.g., by removing one or more components of a primary sample and/or by adding one or more reagents thereto). For example, filtration using a semipermeable membrane. Such "processed sample" may include, for example, nucleic acids or proteins extracted from the sample, or obtained by subjecting the original sample to techniques such as amplification or reverse transcription of mRNA, separation and/or purification of certain components, etc. In some embodiments, the methods disclosed herein do not include a treated sample. In some embodiments, the methods disclosed herein comprise: obtaining a sample from water or other environmental surface, treating the sample to include a known volume, and exposing the sample to an antibody, antibody fragment, system, or composition disclosed herein.
The term "transcriptome" as used herein refers to a nucleic acid sequence that is transcribed by one or more cells in a sample. In some embodiments, the sample comprises one or more hyperproliferative cells.
As used herein, "whole blood" refers to blood obtained directly from a subject and not treated with filtration or additives prior to manipulation. In some embodiments, the whole blood may include an anticoagulant. In some embodiments, the whole blood does not contain an anticoagulant.
"sequence identity" as used herein is determined by explosion of two sequences (B12seq) using an independently executable B L AST engine program, which can be retrieved from the National Center for Biotechnology Information (NCBI) ftp site using default parameters (Tatusova and Madden, FEMS Microbiol L et., 1999,174, 247-250; which is incorporated herein by reference in its entirety.) the term "homology" is used to refer to a measured "sequence identity". in some embodiments, if one embodiment comprises a nucleic acid sequence or amino acid sequence having a percent sequence identity, the term refers to the disclosed nucleic acid sequence or amino acid sequence having homology to the disclosed sequence over its entire length.
The term "clonality score" refers to the numerical solution obtained after solving the IgH values corresponding to those nucleic acid sequences from the samples or those samples having a more extensive clonal expansion of B lymphocytes, whether or not the samples are cancerous tissue. In some embodiments, if the value is about 0.1 or higher, the clonality score is considered to have a broader clonal expansion. In some embodiments, if the value is about 0.15 or higher, the clonality score is considered to have a broader clonal expansion. In some embodiments, if the value is about 0.2 or higher, the clonality score is considered to have a broader clonal expansion. In some embodiments, if the value is about 0.25 or higher, the clonality score is considered to have a broader clonal expansion. In some embodiments, if the value is about 0.3 or higher, the clonality score is considered to have a broader clonal expansion. In some embodiments, if the value is about 0.4 or higher, the clonality score is considered to have a broader clonal expansion. In some embodiments, if the value is about 0.5 or higher, the clonality score is considered to have a broader clonal expansion. In some embodiments, if the value is about 0.6 or higher, the clonality score is considered to have a broader clonal expansion. In some embodiments, if the value is about 0.7 or higher, the clonality score is considered to have a broader clonal expansion. In some embodiments, if the value is about 0.8 or higher, the clonality score is considered to have a broader clonal expansion. In some embodiments, if the value is about 0.9 or higher, the clonality score is considered to have a broader clonal expansion. In some embodiments, if the value is about 1. or higher, the clonality score is considered to have a broader clonal expansion. In some embodiments, if the value is about 0.35 or higher, the clonality score is considered to have a broader clonal expansion.
Method of producing a composite material
The present invention relates to a method for identifying one or more nucleic acid sequences encoding an antibody or antibody fragment from a transcriptome or genomic DNA sequence of a sample, said method comprising: a. screening the transcriptome or genomic DNA sequences of the sample for enriched nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences; b. calculating a clonality score for the sample; c. classifying at least one nucleic acid sequence into the first set or the second set of nucleic acid sequences based on sequence alignment between an Ig-like sequence in a sample or a nucleic acid homologous to a CDR3 (as compared to a V, J, D sequence in the sample or to the Ig-like sequence identified in a control set of samples). In some embodiments, the method further comprises the steps of: (d) after performing the step of classifying, identifying from the first set of nucleic acid sequences a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable strand. In some embodiments, the method further comprises repeating the steps of identifying a nucleic acid sequence encoding at least one CDR of the variable chain and editing a plurality of CDR sequences from the sample. In some embodiments, the method further comprises identifying a nucleic acid sequence encoding at least one CDR of the variable chain and editing the plurality of CDR sequences in the sample based on one or a combination of: the clonality score, presence or abundance of the enrichment of CDR3 or Ig-like nucleic acid sequences in the sample and the alignment of CDR sequences to CDR3 or Ig-like nucleic acid sequences in the sample. In some embodiments, the method further comprises: screening the transcriptomes of a series of control subjects for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences; calculating a clonality score for the series of control samples; identifying the most enriched CDR3 sequence from the sample or series of samples; and obtaining a set of abundantly expressed nucleic acid sequences encoding antibody fragments from the series of control subjects and comparing the first set of nucleic acid sequences from the series of control subjects with the first set of nucleic acid sequences from the subjects, wherein steps (e) to (h) are performed before, simultaneously with or after steps (a) to (c) corresponding to those subparts of the claims, and wherein the step of identifying from the subject's transcriptome a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable chain is based on the step of comparing the sets of abundantly expressed nucleic acid sequences from step (h) corresponding to those steps in the claims disclosed herein.
In some embodiments, the control sample is from a public database of transcriptomes. In some embodiments, the public database comprises transcriptomes from known cancer tissues. In some embodiments, the public database comprises transcriptomes from known cancer tissues that can be classified based on cancer type. In some embodiments, the public database comprises data from known cancer tissues from one or more cancer tissues identified herein. In some embodiments, the public database comprises transcriptomes from known cancer tissues, the public database is a TGCA database.
The present invention also relates to a computer-implemented method for detecting the presence of a nucleic acid sequence encoding an antibody or antibody fragment in a transcriptome of a sample, the method comprising: in a system comprising at least one processor and a memory; a. screening, by the at least one processor, the transcriptome of the subject for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences; b. calculating, by the at least one processor, a clonality score; and separating, by the at least one processor, the nucleic acid sequences into the first set of nucleic acid sequences and the second set of nucleic acid sequences according to the clonality score. In some embodiments, the method further comprises the steps of: (d) after performing the step of classifying, identifying from the first set of nucleic acid sequences a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable strand.
In any of the disclosed methods, in some embodiments, the sample is a cancer tissue selected from the following cancers: glioblastoma multiforme, low-grade gliomas, lung adenocarcinomas, lung squamous carcinomas, pancreatic adenocarcinomas and skin cancers.
A method of designing an antibody or antibody fragment capable of binding a cellular epitope from a sample, the method comprising: (a) obtaining at least one nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of a variable strand from a transcriptome of the subject by the method of any one of claims 1 to 25; and repeating step (a) until a plurality of nucleic acid sequences encoding the antibody or antibody fragment are aggregated from the sample; (b) cloning one or more nucleic acids in a vector or synthesizing the antibody by solid state chemical synthesis; and if the one or more nucleic acid sequences are cloned into a vector, (c) converting the vector into a host cell, and (d) allowing sufficient time for the host cell to recombinantly produce the encoded antibody or antibody fragment.
The present invention also relates to methods of treating a subject diagnosed with or suspected of having a hyperproliferative disease, comprising administering to the subject any one or combination of the pharmaceutical compositions disclosed herein. In some embodiments, the pharmaceutical composition comprises an effective amount of an antibody or antibody fragment disclosed herein or a salt thereof. In some embodiments, the hyperproliferative disease is selected from the group consisting of cancers of: glioblastoma multiforme, low-grade gliomas, lung adenocarcinomas, lung squamous carcinomas, pancreatic adenocarcinomas and skin cancers.
Computer-implemented method
In some embodiments, the invention relates to a computer-implemented method of detecting, classifying, or editing one or more nucleic acid sequences encoding one or more antibodies or antibody fragments from a transcriptome of a sample. In some embodiments, the method comprises an internet-accessible device capable of performing one or more method steps, the method comprising: identifying one or more nucleic acid sequences encoding an antibody or antibody fragment from a transcriptome of a subject, said identifying one or more nucleic acid sequences encoding an antibody or antibody fragment from a transcriptome of a subject comprising: screening the transcriptome of the subject for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences; calculating a clonality score corresponding to one or more nucleic acid sequences in each of the first and second sets of nucleic acid sequences, and classifying the nucleic acid sequences into the first and second sets of nucleic acid sequences based on the clonality score.
In some embodiments, the invention relates to a system comprising a processor that performs a computer-implemented method of identifying one or more nucleic acid sequences encoding an antibody or antibody fragment from a transcriptome of a subject, the method comprising: screening the transcriptome of the subject for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences; calculating a clonality score corresponding to one or more nucleic acid sequences in each of the first and second sets of nucleic acid sequences, and classifying the nucleic acid sequences into the first and second sets of nucleic acid sequences based on the clonality score.
In some embodiments, the invention relates to a system comprising a processor that executes a computer-implemented method of detecting exit behavior of a user device accessing the internet, the method comprising screening a nucleic acid sequence encoding one or more antibody fragments in the transcriptome of a series of control subjects, wherein the nucleic acid sequence encoding one or more antibody fragments comprises a first set of abundantly-expressed nucleic acid sequences and a second set of rarely-expressed nucleic acid sequences, calculating a clonality score corresponding to one or more nucleic acid sequences in each of the first and second sets of nucleic acid sequences and dividing the nucleic acid sequences into the first and second sets of nucleic acid sequences based on the clonality score, and obtaining the set of abundantly-expressed nucleic acid sequences encoding antibody fragments from the series of control subjects and comparing the first set of nucleic acid sequences from the series of control subjects with the first set of nucleic acid sequences from the subjects based on the clonality score, and in some embodiments, the invention relates to a system comprising at least one processor and computer memory, the computer-readable code and/or other computer-readable storage means for storing the computer-readable code and/or computer-readable data for use in detecting the presence of the system, such as a computer-accessible computer-based on a computer-processing system, a computer-based on a computer-readable storage device, and/or computer-based on a computer-processing system, or computer-based on-readable storage-computer-based system-or computer-readable data-processing device, such as-processing system-or computer-readable data-processing device, or computer-based system-computer-readable storage device, or computer-readable data-computer-readable data-computer-readable storage device, or computer-computer.
In some embodiments, the invention relates to a computer-implemented method of identifying sequences from genomic DNA or transcriptome of nucleic acid sequences in a sample that are encoding antibodies or antibody fragments that bind cancer tissue more efficiently than antibodies or antibody fragments identified from clonal amplification of cells of the same tissue.
Exemplary embodiments include the following, and reference is made to the numbering of the claim-like language on page 71 of the specification:
1. a method of identifying one or more nucleic acid sequences encoding an antibody or antibody fragment from a transcriptome or genomic DNA sequence of a sample, the method comprising:
a. screening the transcriptome or genomic DNA sequences of the sample for enriched nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences;
b. calculating a clonality score for the sample;
c. the nucleic acid sequences are divided into the first set of nucleic acid sequences and the second set of nucleic acid sequences according to a sequence alignment.
2. The method of claim 1, further comprising the steps of: (d) after performing the step of classifying, identifying from the first set of nucleic acid sequences a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable strand.
3. The method of claim 2, further comprising repeating the steps of identifying a nucleic acid sequence encoding at least one CDR of the variable chain and editing the plurality of CDR sequences.
4. The method of claim 2, further comprising:
e. screening the transcriptomes of a series of control subjects for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences;
f. calculating a clonality score for the sample;
g. identifying the most enriched CDR3 sequence from the sample or series of samples;
h. obtaining a set of abundantly expressed nucleic acid sequences encoding antibody fragments from the series of control subjects and comparing the nucleic acid sequences of the first set from the series of control subjects to the first set of nucleic acid sequences from the subjects;
wherein steps (e) to (h) are performed before, simultaneously with or after steps (a) to (c);
and wherein said step of identifying from the subject's transcriptome a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable strand is based on said step of comparing sets of abundantly expressed nucleic acid sequences from step (h).
5. The method of any one of claims 1 to 5, wherein the first set of abundantly expressed nucleic acid sequences from the subject encodes one or a combination of antibody fragments selected from: an Fc portion of an antibody, a single chain variable fragment of an antibody (ScFv), an Fv portion of an antibody, an Fab fragment of an antibody, an F (ab')2 fragment of an antibody, an Fd fragment of an antibody, an IgG-like fragment of an antibody, a variable chain of an antibody, and a constant region of an antibody.
6. The method of any one of claims 1 to 5, wherein the first set of abundantly expressed nucleic acid sequences from the subject encodes one or a combination of variable heavy and/or variable light portions of the antibody.
7. The method of any one of claims 1 to 6, wherein the screening step comprises screening for nucleic acid sequences encoding antibody fragments of one or more B Cell Receptor (BCR) sequences, and the step of calculating a clonality score for a sample is determined at least in part by the equation:
where Ci is the clone score of rearrangement i and N is the total number of rearrangements.
8. The method of any one of claims 1 to 7, wherein said screening the transcriptome or genomic DNA of a series of samples for nucleic acid sequences encoding one or more antibody fragments comprises performing FASTQ, MIXCR, and VDJtools functions on the transcriptome data.
9. The method of any one of claims 1 to 8, wherein screening the transcriptome or genomic DNA of the sample for nucleic acid sequences encoding one or more antibody fragments comprises performing an alignment of cloned sequences.
10. The method of claim 9, wherein the alignment of cloned sequences comprises performing an immunizing SEQ function.
11. The method of any one of claims 1 to 10, wherein the sample is a tissue sample from a subject having a hyperproliferative cellular disease.
12. The method of any one of claims 1 to 10, wherein the sample is a cancer tissue selected from the following cancers: glioblastoma multiforme, low-grade gliomas, lung adenocarcinomas, lung squamous carcinomas, pancreatic adenocarcinomas and skin cancers.
13. A computer-implemented method for detecting the presence of a nucleic acid sequence encoding an antibody or antibody fragment in a transcriptome of a sample, the method comprising: at least one processor and memory are included in the system.
a. Screening, by the at least one processor, the transcriptome of the subject for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences;
b. calculating, by the at least one processor, a clonality score;
c. separating, by the at least one processor, the nucleic acid sequences into the first set of nucleic acid sequences and the second set of nucleic acid sequences according to the clonality score.
14. The method of claim 13, further comprising the steps of: (d) after performing the step of classifying, identifying from the first set of nucleic acid sequences a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable strand.
15. The method of claim 14, further comprising repeating the steps of identifying a nucleic acid sequence encoding at least one CDR of the variable chain and editing the plurality of CDR sequences.
16. The method of claim 14, further comprising:
e. screening the transcriptomes of a series of control subjects for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences;
f. calculating a clonality score corresponding to one or more of the nucleic acid sequences in each of the first and second sets of nucleic acid sequences;
g. dividing the nucleic acid sequences into the first set of nucleic acid sequences and the second set of nucleic acid sequences based on the clonality score;
h. obtaining a set of abundantly expressed nucleic acid sequences encoding antibody fragments from the series of control subjects and comparing the nucleic acid sequences of the first set from the series of control subjects to the first set of nucleic acid sequences from the subjects;
wherein steps (e) to (h) are performed before, simultaneously with or after steps (a) to (c);
and wherein said step of identifying from the subject's transcriptome a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable strand is based on said step of comparing sets of abundantly expressed nucleic acid sequences from step (h).
17. The method of any one of claims 13 to 16, wherein the first set of abundantly expressed nucleic acid sequences from the subject encodes one or a combination of antibody fragments selected from: an Fc portion of an antibody, a single chain variable fragment of an antibody (ScFv), an Fv portion of an antibody, an Fab fragment of an antibody, an F (ab')2 fragment of an antibody, an Fd fragment of an antibody, an IgG-like fragment of an antibody, a variable chain of an antibody, and a constant region of an antibody.
18. The method of any one of claims 13 to 17, wherein the first set of abundantly expressed nucleic acid sequences from the subject encodes one or a combination of variable heavy and/or variable light portions of the antibody.
19. The method of any one of claims 13 to 18, wherein the screening step comprises screening for nucleic acid sequences encoding antibody fragments of one or more B Cell Receptor (BCR) sequences, and the step of calculating a clonality score for a sample is determined at least in part by the equation:
wherein Ci is the clone score of rearrangement i and N is the total number of rearrangements; and wherein said classifying nucleic acids into said first set of nucleic acid sequences is performed if said score is 0.1 or higher.
20. The method of any one of claims 16 to 19, wherein said screening the transcriptome of a series of samples for nucleic acid sequences encoding one or more antibody fragments comprises performing FASTQ, MIXCR, and vdjsols functions on the transcriptome data.
21. The method of any one of claims 13 to 20, wherein said screening the transcriptome of said subject for nucleic acid sequences encoding one or more antibody fragments comprises performing an alignment of cloned sequences.
22. The method of claim 21, wherein the alignment of cloned sequences comprises performing an immunizing SEQ function.
23. The method of any one of claims 13 to 22, wherein the sample is a tissue sample from a subject having a hyperproliferative cellular disease.
24. The method of any one of claims 13 to 23, wherein the sample is a cancer tissue selected from the following cancers: glioblastoma multiforme, low-grade gliomas, lung adenocarcinomas, lung squamous carcinomas, pancreatic adenocarcinomas and skin cancers.
25. The method of claim 1 or 13, wherein the first set of nucleic acids encoding antibodies or antibody fragments encodes antibodies capable of binding to one or more cells from the sample and/or subject.
26. A method of editing a set of nucleic acid sequences encoding an antibody or antibody fragment from a sample, the method comprising:
(a) obtaining at least one nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of a variable strand from a transcriptome of the subject by the method of any one of claims 1 to 25; and
(b) repeating step (a) until a plurality of nucleic acid sequences encoding the antibody or antibody fragment are aggregated from the sample.
Compositions comprising antibodies
The present invention relates to one or more pharmaceutical compositions comprising an effective amount of one or more of the antibodies disclosed herein, antibody fragments disclosed herein, or salts thereof, and one or more pharmaceutically acceptable carriers.
The invention features antibodies or antigen-binding fragments thereof that bind to tumor tissue. In certain embodiments, the antibodies or antigen-binding fragments thereof of the invention are cross-reactive between tissue samples of different cancer types, but do not bind to normal tissue. In other embodiments, the antibodies or antigen binding fragments thereof of the invention selectively bind to one type of tumor tissue.
Exemplary cancers include, but are not limited to, acute lymphocytic leukemia (A LL), acute myelocytic leukemia (AM L), adrenal cancer, anal cancer, basal and squamous cell skin cancer, biliary tract cancer, bladder cancer, bone cancer, brain and spinal cord tumors, breast cancer, cervical cancer, chronic lymphocytic leukemia (C LL), chronic myelogenous leukemia (CM L), chronic myelomonocytic leukemia (CMM L) colorectal cancer, endometrial cancer, esophageal cancer, Ewing's family tumor, eye cancer, gall bladder cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors (GIST), gestational trophoblastic disease, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, larynx and hypopharynx cancer, leukemia, liver cancer, lung cancer, carcinoid tumors, lymphoma, skin lymphoma, malignant mesothelioma, melanoma skin cancer, thymocyte skin cancer, multiple myeloma, myelodysplasia syndrome, nasal cavity and paranasal sinuses, nasopharyngeal carcinoma, neuroblastoma, non-Hodgkin's lymphoma, non-hodgkin's lymphoma, non-small cell lung cancer, oral cancer, osteosarcoma, penile sarcoma, testicular cancer, pancreatic cancer, thyroid cancer, pancreatic cancer, uterine sarcoma, pancreatic cancer.
In some embodiments, the invention relates to a method comprising: antibody specificity was verified using immunofluorescence methods known in the art by comparing antibody binding to cancer and normal tissues.
In some embodiments, the invention relates to a composition that has broad reactivity against cancer tissue but little antibody against normal tissue.
In some embodiments, the invention relates to a composition of cancer specific antibodies having the amino acid sequence identified in sequence ID 1-9.
In some embodiments, the invention relates to a composition of antibodies having a narrow specificity for tissue in which antibody sequences are synthesized from immune sequence data.
In some embodiments, the invention relates to a composition comprising a single cancer specific antibody according to claim 45 having the amino acid sequence identified in sequence ID 10-18.
In some embodiments, the invention relates to immune sequence-derived high abundance antibody sequences including CDR1, CDR2, and CDR3, as well as somatic mutated sequences.
In some embodiments, the invention relates to an immune sequence derived sequence from the cancer assembly of claim 48 comprising one of the sequences of sequence ID 19.
In some embodiments, the invention relates to the use of antibodies constructed by the sequences of claims 42-48 in cancer diagnosis, comprising immunohistochemical staining of tissues by immunofluorescence.
In some embodiments, the antibodies are modified for optimal antibody-dependent cellular cytotoxicity or antibody-dependent phagocytosis.
In some embodiments, the antibody or fragment thereof or salt thereof is used as an antibody-drug conjugate.
In some embodiments, the antibodies are used as components of bispecific antibodies. In some embodiments, the antibodies are used as a key component of chimeric antigen receptor T Cells (CART).
In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2206; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2208; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2210; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO 2216; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2218; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO 2220. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO. 2226; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence as set forth in SEQ ID NO. 2228; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2230; a light chain CDR1, said light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2236; a light chain CDR2, said light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2238; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2240. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2246; heavy chain CDR2, said heavy chain CDR2 comprises an amino acid sequence set forth in SEQ ID NO: 2248; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO 2250; a light chain CDR1, said light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO 2256; a light chain CDR2, said light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO 2258; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2260. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2266; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2268; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown as SEQ ID NO: 2270; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2276; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2278; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO 2280. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO. 2286; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO 2288; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO. 2290; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2296; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO 2298; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2300. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2306; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2308; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2310; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2316; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2318; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2320. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2326; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2328; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2330; a light chain CDR1, said light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2336; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2338; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2340. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence as set forth in SEQ ID NO: 2346; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence as set forth in SEQ ID NO: 2348; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 2350; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2356; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2358; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2360. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2366; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2368; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2370; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2376; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2378; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2380. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2386; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2388; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2390; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2396; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2398; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO 2400. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising the amino acid sequence shown in SEQ ID NO: 2406; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2408; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2410; a light chain CDR1, said light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2416; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2418; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO. 2420. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2426; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2428; a heavy chain CDR3, the heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2430; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2436; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2438; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2440. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, the heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2446; a heavy chain CDR2, the heavy chain CDR2 comprising an amino acid sequence as set forth in SEQ ID NO: 2448; a heavy chain CDR3, said heavy chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2450; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2456; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2458; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2460. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, the heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2466; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2468; a heavy chain CDR3, the heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2470; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2476; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2478; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2480. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, the heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2486; a heavy chain CDR2, the heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2488; a heavy chain CDR3, the heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2490; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2496; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2498; and a light chain CDR3, the light chain CDR3 including the amino acid sequence set forth in SEQ ID NO: 2500. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2506; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2508; a heavy chain CDR3, wherein the heavy chain CDR3 comprises an amino acid sequence shown as SEQ ID NO: 2510; a light chain CDR1, said light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2516; a light chain CDR2, said light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2518; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2520. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence as shown in SEQ ID NO: 2526; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence as shown in SEQ ID NO: 2528; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2530; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2536; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2538; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2540. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2546; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2548; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2550; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2556; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2558; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2560. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2566; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2568; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2570; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2576; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2578; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2580. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2586; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2588; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2590; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2596; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2598; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2600. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2606; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2608; a heavy chain CDR3, said heavy chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2610; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2616; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2618; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2620. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence as set forth in SEQ ID NO: 2626; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2628; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2630; a light chain CDR1, the light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2636; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2638; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2640. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2646; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2648; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2650; a light chain CDR1, the light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2656; a light chain CDR2, the light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2658; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2660. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2666; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence shown in SEQ ID NO: 2668; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2670; a light chain CDR1, the light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2676; a light chain CDR2, the light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2678; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2680. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2686; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2688; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2690; a light chain CDR1, the light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2696; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2698; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2700. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2706; heavy chain CDR2, said heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 2708; heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence as shown in SEQ ID NO: 2710; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2716; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2718; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO 2720.
One or more CDRs may be incorporated covalently or non-covalently into a molecule to make it an antigen binding protein.
An antigen binding protein can incorporate a CDR as part of a larger polypeptide chain, can covalently link a CDR to another polypeptide chain, or can non-covalently incorporate a CDR. The CDRs allow the antigen binding protein to specifically bind to a particular antigen of interest.
In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof having an antigen-binding region of any of the antibodies described in table 17.
In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2204 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2204, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2214 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2214. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2224 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2224, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2234 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2234. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO 2244 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2244, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO 2254 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2254. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO 2264 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2264, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO 2274 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2274. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence set forth as SEQ ID NO. 2284 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO. 2284, and/or a light chain variable domain comprising the amino acid sequence set forth as SEQ ID NO. 2294 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO. 2294. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2304 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2304, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2314 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2314. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2324 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2324, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2334 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2334. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2344 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2344, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2354 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2354. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2364 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2364, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2374 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2374. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2384 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2384, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2394 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2394. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2404 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2404, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2414 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2414. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2424 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2424, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2434 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2434. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2444 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2444, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2454 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2454. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2464 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2464, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2474 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2474. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2484 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2484, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2494 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2494. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising an amino acid sequence as set forth in SEQ ID NO. 2504 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2504, and/or a light chain variable domain comprising an amino acid sequence as set forth in SEQ ID NO. 2514 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2514. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2524 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2524, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2534 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2534. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2544 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2544, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2554 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2554. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2564 or a sequence at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO. 2564, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2574 or a sequence at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO. 2574. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2584 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2584, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2594 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2594. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2604 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2604, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2614 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2614. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2624 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2624, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2634 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2634. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2644 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2644, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2654 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2654. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2664 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2664, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2674 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2674. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2684 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2684, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2694 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2694. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2704 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2704, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2714 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2714.
In another embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2202 or a sequence at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:2202, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2212 or a sequence at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 2212. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2222 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2222, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO. 2232 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2232. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO 2242 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2242, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO 2252 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2252. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO 2262 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2262, and/or a light chain comprising the amino acid sequence as set forth in SEQ ID NO 2272 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2272. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO. 2282 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2282, and/or a light chain comprising the amino acid sequence as set forth in SEQ ID NO. 2292 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2292. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2302 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2302, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO. 2312 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2312. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2322 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2322, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2332 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2332. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2342 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2342, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2352 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2352. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO:2362 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2362, and/or a light chain comprising the amino acid sequence as set forth in SEQ ID NO:2372 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2372. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO:2382 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2382, and/or a light chain comprising the amino acid sequence as set forth in SEQ ID NO:2392 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2392. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO 2402 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2402, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO 2412 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2412. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID No. 2422 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID No. 2422, and/or a light chain comprising the amino acid sequence shown as SEQ ID No. 2432 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID No. 2432. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2442 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2442, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2452 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2452. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2462 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2462, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2472 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2472. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2482 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2482, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2492 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2492. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2502 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2502, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO. 2512 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2512. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2522 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2522, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO. 2532 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2532. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2542 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2542, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO. 2552 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2552. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2562 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2562, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO. 2572 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2572. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2582 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2582, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO. 2592 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2592. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2602 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2602, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2612 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2612. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2622 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2622 and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2632 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2632. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2642 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2642, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2652 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2652. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2662 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2662, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2672 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2672. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2682 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2682, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2692 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2692. In one embodiment, the invention relates to an antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising: a heavy chain comprising the amino acid sequence shown as SEQ ID NO 2702 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2702, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO 2712 or a sequence having at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO 2712.
In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO 2202 and the light chain comprises the amino acid sequence set forth in SEQ ID NO 2212. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO. 2222 and the light chain comprises the amino acid sequence set forth in SEQ ID NO. 2232. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2242 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 2252. In certain embodiments, the heavy chain comprises the amino acid sequence set forth as SEQ ID NO:2262 and the light chain comprises the amino acid sequence set forth as SEQ ID NO: 2272. In certain embodiments, the heavy chain comprises the amino acid sequence set forth as SEQ ID NO. 2282 and the light chain comprises the amino acid sequence set forth as SEQ ID NO. 2292. In certain embodiments, the heavy chain comprises the amino acid sequence shown as SEQ ID NO 2302 and the light chain comprises the amino acid sequence shown as SEQ ID NO 2312. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO 2322 and the light chain comprises the amino acid sequence set forth in SEQ ID NO 2332. In certain embodiments, the heavy chain comprises the amino acid sequence shown as SEQ ID NO:2342 and the light chain comprises the amino acid sequence shown as SEQ ID NO: 2352. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2362 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 2372. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2382 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 2392. In certain embodiments, the heavy chain comprises the amino acid sequence shown as SEQ ID NO 2402 and the light chain comprises the amino acid sequence shown as SEQ ID NO 2412. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2422 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 2432. In certain embodiments, the heavy chain comprises the amino acid sequence set forth as SEQ ID NO:2442 and the light chain comprises the amino acid sequence set forth as SEQ ID NO: 2452. In certain embodiments, the heavy chain comprises the amino acid sequence set forth as SEQ ID NO:2462 and the light chain comprises the amino acid sequence set forth as SEQ ID NO: 2472. In certain embodiments, the heavy chain comprises the amino acid sequence set forth as SEQ ID NO:2482 and the light chain comprises the amino acid sequence set forth as SEQ ID NO: 2492. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO 2502 and the light chain comprises the amino acid sequence set forth in SEQ ID NO 2512. In certain embodiments, the heavy chain comprises the amino acid sequence shown as SEQ ID NO:2522 and the light chain comprises the amino acid sequence shown as SEQ ID NO: 2532. In certain embodiments, the heavy chain comprises the amino acid sequence set forth as SEQ ID NO:2542 and the light chain comprises the amino acid sequence set forth as SEQ ID NO: 2552. In certain embodiments, the heavy chain comprises the amino acid sequence shown as SEQ ID NO 2562 and the light chain comprises the amino acid sequence shown as SEQ ID NO 2572. In certain embodiments, the heavy chain comprises the amino acid sequence shown as SEQ ID NO 2582 and the light chain comprises the amino acid sequence shown as SEQ ID NO 2592. In certain embodiments, the heavy chain comprises the amino acid sequence set forth as SEQ ID NO:2602 and the light chain comprises the amino acid sequence set forth as SEQ ID NO: 2612. In certain embodiments, the heavy chain comprises the amino acid sequence set forth as SEQ ID NO:2622 and the light chain comprises the amino acid sequence set forth as SEQ ID NO: 2632. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2642 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 2652. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2662 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 2672. In certain embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2682 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 2692. In certain embodiments, the heavy chain comprises the amino acid sequence shown as SEQ ID NO 2702 and the light chain comprises the amino acid sequence shown as SEQ ID NO 2712.
In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2202. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2212. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2222. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2232. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2242. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2252. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ id no: 2262. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2272. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ id No. 2282. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2292. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2302. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2312. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2322. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2332. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2342. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2352. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2362. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ id No. 2372. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2382. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2392. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2402. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2412. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2422. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2432. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2442. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2452. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ id no: 2462. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2482. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2492. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2502. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2512. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2522. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2532. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2542. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2552. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2562. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ id No. 2572. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2582. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2592. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence that includes 2602. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2612. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2622. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2632. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2642. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2652. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2662. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2672. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2682. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO: 2692. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID No. 2702. In some embodiments, the composition or pharmaceutical composition is free of an amino acid sequence comprising SEQ ID NO 2712.
In certain embodiments, the antibodies include heavy chain constant regions, such as IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM, or IgD constant regions in certain embodiments of the invention, the antibodies or antigen-binding fragments are classified as isotypes selected from the group consisting of IgG, IgM, IgD, IgA, and IgE.
In addition, the antibody can include a light chain constant region, a kappa light chain constant region, or a lambda light chain constant region.
In certain embodiments of the invention, the antibody or antigen binding fragment is selected from the group consisting of Fab, Fab ', F (ab')2, Fv, domain antibodies, and single chain antibodies.
In other embodiments, an antibody or antigen-binding fragment thereof that binds to tumor tissue competes with an antibody or antigen-binding fragment thereof described in table 17. In particular embodiments, the competing antibody, or antigen-binding portion thereof, is an antibody, or antigen-binding portion thereof, that competes with any of the antibodies described herein. In one embodiment, the invention provides a competitive antibody that can compete with the antibody described herein.
The present invention provides a plurality of antibodies that are structurally characterized by the amino acid sequences of their variable domain regions. However, the amino acid sequence may undergo some changes while also retaining a high degree of binding to its specific target. More specifically, many amino acids in the variable domain region can be altered by conservative substitutions, and it is expected that the binding characteristics of the resulting antibody will not differ from the binding characteristics of the wild-type antibody sequence. Many amino acids in the antibody variable domain do not interact directly with the antigen or affect antigen binding and are not critical to determining antibody structure. For example, it is preferred to replace a predicted nonessential amino acid residue in any of the disclosed antibodies with another amino acid residue of the same class. Methods for identifying conservative substitutions of amino acids that do not eliminate antigen binding are well known in the art (see, for example, Brummell et al, biochem.32:1180-1187 (1993); Kobayashi et al, Protein Eng.12(10):879-884 (1999); and Burks et al, Proc. Natl. Acad. Sci. USA 94:412-417(1997), all of which are incorporated herein by reference in their entirety). Near et al explain in mol.Immunol.30:369-377,1993 how binding can be influenced or not by site-directed mutagenesis. Near et al believe that only the mutated residues have the potential to alter antigen binding. Most had a moderate or negative effect on binding affinity (Near et al, table 3) and bound to different forms of digoxin (Near et al, table 2).
Conservative modifications or functional equivalents of the disclosed peptides, polypeptides, or proteins (e.g., a hinge region or a heavy chain having a hinge region) refer to polypeptide derivatives of the peptides, polypeptides, or proteins, such as proteins having one or more point mutations, insertions, deletions, truncations, fusion proteins, or combinations thereof. Which substantially retains the activity of a parent peptide, polypeptide or protein, such as those disclosed herein. Typically, conservative modifications or functional equivalents are at least 60% (e.g., any number between 60% and 100%, including, for example, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, and 99%) identical to a parent (e.g., one of SEQ ID NOs: 1-53).
In one embodiment, a substitution that is at least 95% identical (or at least 96% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical) in the heavy or light chain is a conservative amino acid substitution. A "conservative amino acid substitution" is one in which an amino acid residue is replaced with another amino acid residue having a similar chemical property (e.g., charge or hydrophobicity) with a side chain (R group). In general, conservative amino acid substitutions do not substantially alter the functional properties of the protein. In the case where two or more amino acid sequences differ from each other by conservative substitutions, the percentage of sequence identity or similarity may be adjusted upward to correct for the conservative nature of the substitution. Methods of making such adjustments are well known to those of ordinary skill in the art. See, for example, Pearson (1994) Methods mol. biol.24: 307-. Examples of amino acid groups having side chains with similar chemical properties include: (1) aliphatic side chain: glycine, alanine, valine, leucine, and isoleucine; (2) aliphatic hydroxyl side chain: serine and threonine; (3) amide-containing side chains: asparagine and glutamine; (4) aromatic side chain: phenylalanine, tyrosine and tryptophan; (5) basic side chain: lysine, arginine and histidine; (6) acidic side chain: aspartic acid and glutamic acid; (7) the sulfur-containing side chains are cysteine and methionine.
As used herein, the percent homology between two amino acid sequences is equivalent to the percent identity between the two sequences. Given the number of gaps and the length of each gap (which need to be introduced to achieve optimal alignment of the two sequences), the percent identity between two sequences is a function of the number of identical positions shared by the sequences (i.e.,% homology-number of identical positions/total number of positions x 100). Comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the following non-limiting examples.
The algorithms of e.meyers and w.miller (comput. appl. biosci.,4:11-17(1988)), which have incorporated the a L IGN program (version 2.0), can be used to determine the percent identity between two sequences using the PAM120 weight residue table, GAP length penalty 12 and GAP penalty 4. in addition, Needleman and Wunsch (j.mol. biol.48:444-453(1970)) algorithms, which have incorporated the GAP program in the GCG software package (reviewed on www.gcg.com), can be used to determine the percent identity between two sequences using either the Blossum62 matrix or the PAM250 matrix, the GAP weights 16, 14, 12, 10, 8, 6 or 4, the length weights 1, 2, 3, 4,5 or 6.
Additionally or alternatively, protein sequences of the present disclosure may also be used as "query sequences" to search public databases, for example to identify related sequences, these searches may be conducted using the XB L AST program (version 2.0) of Altschul et al (1990) j.mol.biol.215:403-10. B L AST protein searches may be conducted using the XB L AST program, with a score of 50 and a word length of 3, to obtain amino acid sequences homologous to the molecules of the present invention.
Other modified forms of antibodies are contemplated herein. For example, the antibody can be linked to one of a variety of non-protein polymers, e.g., polyethylene glycol, polypropylene glycol, polyoxyalkylene, or a copolymer of polyethylene glycol and polypropylene glycol. The antibody may also be embedded in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (e.g., hydroxymethylcellulose or gelatin microcapsules and poly (methylmethacylate) microcapsules, respectively), in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or macroemulsions. Such techniques are disclosed, for example, in the Remington's Pharmaceutical Sciences 16 th edition Oslo, A., Ed. (1980).
Variant antibodies and salts thereof are included within the scope of the invention. Variants of the sequences described herein are also included within the scope of the invention. Other variants of antibodies with improved affinity may be obtained using methods known in the art and are included within the scope of the invention. For example, amino acid substitutions may be used to obtain antibodies with further improved affinity. Alternatively, codon optimization of the nucleotide sequence can be used to increase the translation efficiency of antibody production in an expression system. Variants may include up to a certain percentage of unnatural amino acids. In some embodiments, the antibody comprises a variant amino acid sequence comprising about 1, 2, 3, 4,5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more percent of unnatural amino acids
Antibody modification
Humanization
In the case of antibodies or antigen-binding fragments thereof that are non-human antibodies, the antibodies may be "humanized" to reduce immunogenicity to human recipients. Methods for humanizing non-human antibodies have been described in the art. See, for example, Jones et al, Nature321:522-525 (1986); riechmann et al, Nature 332:323-327 (1988); verhoeyen et al, Science 239:1534-1536(1988) and U.S. Pat. No.4,816,567. Typically, residues from the variable domains of non-human antibodies are "introduced" into human immunoglobulin molecules, resulting in antibodies in which some hypervariable region residues and possibly some FR residues of the human antibody are substituted by residues from analogous sites in the non-human antibody. It is important to humanize non-human antibodies while maintaining high affinity for the antigen. For this purpose, three-dimensional immunoglobulin models are generally available and are suitable for analyzing proposed humanized sequences, as compared to the parent non-human antibody. Such analysis allows the identification of residues that may be involved in antigen recognition and binding, and thus the rational design of humanized sequences that retain specificity and affinity for the antigen.
As described above, a humanized antibody is an antibody molecule from an antibody of a non-human species that binds a desired antigen having one or more Complementarity Determining Regions (CDRs) from the non-human species and framework regions from a human immunoglobulin molecule. Known human Ig sequences have been disclosed, e.g., www.ncbi.nlm.nih.gov/entrez-/query. fcgi; www.atcc.org/phase/hdb. html; www.sciquest.com/; www.abcam.com/; www.antibodyresource.com/onlinecomp. html;
www.public.iastate.edu/.about.pedro/research_tools.html;www.mgen.uni-heidelberg.de/SD/IT/IT.html;www.whfreeman.com/immunology/CH-05/kuby05.htm;www.library.thinkquest.org/12429/Immune/Antibody.html;
www.hhmi.org/grants/lectures/1996/vlab/;www.path.cam.ac.uk/.about.mrc7/m-ikeimages.html;www.antibodyresource.com/;mcb.harvard.edu/BioLinks/Immuno-logy.html.www.immunologylink.com/;pathbox.wustl.edu/.about.hcenter/index.-html;
www.biotech.ufl.edu/.about.hcl/;www.pebio.com/pa/340913/340913.html-;
www.nal.usda.gov/awic/pubs/antibody/;www.m.ehime-u.acjp/.about.yasuhito-/Elisa.html;www.biodesign.com/table.asp;www.icnet.uk/axp/facs/davies/lin-ks.html;
www.biotech.ufl.edu/.about.fccl/protocol.html;www.isac-net.org/sites_geo.html;aximtl.imt.uni-marburg.de/.about.rek/AEP-Start.html;
baserv.uci.kun.nl/.about.jraats/linksl.html;www.recab.uni-hd.de/immuno.bme.nwu.edu/;
www.mrc-cpe.cam.ac.uk/imt-doc/pu-blic/INTRO.html;
www.ibt.unam.mx/vir/V_mice.html;imgt.cnusc.fr:8104/;
www.biochem.ucl.ac.uk/.about.martin/abs/index.html;antibody.bath.ac.uk/;
abgen.cvm.tamu.edu/lab/wwwabgen.html;www.unizh.ch/.about.honegger/AHOsem-inar/Slide01.html;www.cryst.bbk.ac.uk/.about.ubcg07s/;
www.nimr.mrc.ac.uk/CC/ccaewg/ccaewg.htm;www.path.cam.ac.uk/.about.mrc7/h-umanisation/TAHHP.html;www.ibt.unam.mx/vir/structure/stat_aim.html;
www.biosci.missouri.edu/smithgp/index.html;www.cryst.bioc.cam.ac.uk/.abo-ut.fmolina/Web-pages/Pept/spottech.html;www.jerini.de/fr roducts.htm;
www.patents.ibm.com/ibm. html, Sequences of Proteins of immunological Interest, U.S. dept. health (1983) by Kabat et al, all of which are incorporated herein by reference. Such introduced sequences may be used to reduce immunogenicity or to reduce, enhance or modify binding, affinity, turn-on rate, turn-off rate, affinity, specificity, half-life, or any other suitable characteristic known in the art.
The framework residues in the human framework regions may be substituted by corresponding residues from CDR donor antibodies to alter, preferably improve, antigen binding, these framework substitutions are identified by methods well known in the art, e.g.by modeling the interaction of the CDR and framework residues to identify framework residues important for antigen binding, and by sequence comparison to identify aberrant framework residues at specific positions (see, e.g.Queen et al, U.S. Pat. No.5,585,089; Riechmann et al, 332:323(1988), which are incorporated herein by reference in their entirety). the three-dimensional immunoglobulin model is commonly available and is familiar to the skilled person.A computer program is available which illustrates and shows the possible three-dimensional conformational structure of the selected candidate immunoglobulin sequence. examination of these display phenomena allows analysis of the possible role of residues in the function of the candidate immunoglobulin sequence, i.e.analysis of the residues affecting the ability of the candidate immunoglobulin to bind their antigen, i.e.the introduction of the residues from consensus sequences and binding to the sequences, e.e.the antibodies of WO 36419252,3685, 3685, 3699, 3685, 3670, 369, 3670, 369, 3695, 369.
Affinity maturation
One or more hypervariable region residues of an antibody can be substituted to select variants having improved biological properties relative to the parent antibody by using affinity maturation, for example using phage or yeast display. For example, the Fab region of the antibodies of the invention can be mutated at selected several sites based on available structural information to generate all possible amino substitutions at each site. The antibody variants thus produced are displayed in monovalent form from the surface of a phage particle or yeast cell. The displayed variants are then screened for biological activity (e.g., binding affinity).
Modification of Fc region
Antibodies can be modified to improve certain biological properties of the antibody, for example, to improve antibody stability, to enhance or reduce effector function (e.g., antigen-dependent cell-mediated cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC)) of the antibody, to improve or reduce internalization and/or recovery, and the like.
For example, the Fc fragment of certain antibodies (derived from human Ig4) may be substituted with human IgG1, which human IgG1 increases effector functions mediated by FcR (except FcRn). Such modifications can increase the stability of the resulting antibody by 5-fold. In another example, the IgG1 Fc fragment can be modified to improve recycling of antibodies through antibody rescue pathways.
Another type of modification involves alteration of the glycosylation pattern of the parent antibody, including deletion of one or more carbohydrate moieties found in the parent antibody, or addition of one or more carbohydrates not present in the parent antibody (by addition of one or more glycosylation sites).
Pharmaceutical composition
The invention also provides a pharmaceutical composition comprising an antibody or antigen-binding portion thereof as exemplified herein and a pharmaceutically acceptable carrier.
The pharmaceutical compositions of the invention may comprise a "therapeutically effective amount" or a "prophylactically effective amount" of an antibody or antibody portion of the invention. A "therapeutically effective amount" is an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of an antibody or antibody portion can be determined by one of skill in the art and will vary depending on factors such as the disease state, age, sex, and weight of the individual and the ability of the antibody or antibody portion to elicit a desired response in the individual. A therapeutically effective amount is also an amount by which any toxic or deleterious effects of the antibody or antibody portion are offset by a therapeutically beneficial effect. A "prophylactically effective amount" is an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, because a prophylactic dose is used in a subject prior to or at an earlier stage of the disease, the prophylactically effective amount will be less than the therapeutically effective amount.
The antibodies or antibody portions of the invention can be incorporated into pharmaceutical compositions suitable for administration to a subject. Typically, the pharmaceutical composition comprises an antibody or antibody portion of the invention and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Examples of pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and the like, and combinations thereof. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. The pharmaceutically acceptable carrier may also include minor amounts of auxiliary substances, such as wetting or emulsifying agents, preservatives or buffers, which may extend the shelf-life or effectiveness of the antibody or antibody portion.
Various delivery systems are known and can be used to administer one or more antibodies of the invention or a combination of one or more antibodies of the invention and a useful prophylactic or therapeutic agent for methods of preventing, controlling, treating or ameliorating a disease or one or more symptoms thereof (e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing an antibody or antibody fragment), receptor-mediated endocytosis (see, e.g., Wu and Wu, j.biol. chem.262:4429-4432(1987)), nucleic acid construction of a portion of a retrovirus or other vector, and the like. Methods of administering the prophylactic or therapeutic agents of the invention include, but are not limited to, parenteral administration (e.g., intradermal, intramuscular, intraperitoneal, intravenous, and subcutaneous), epidural administration, intratumoral administration, and mucosal administration (e.g., intranasal and oral routes). In addition, pulmonary administration can be carried out, for example, by using an inhaler or nebulizer, and formulated with an aerosolizing agent. See, for example, U.S. patent nos.6,019,968, 5,985,320, 5,985,309, 5,934,272, 5,874,064, 5,855,913, 5,290,540, and 4,880,078; and PCT publication nos. WO92/19244, WO 97/32572, WO 97/44013, WO 98/31346 and WO 99/66903, all of which are incorporated herein by reference in their entirety. In one embodiment, the antibody, combination therapy, or composition of the invention is administered using the Alkermes AIR pulmonary drug delivery technology (Alkermes, inc., Cambridge, Mass.). In a particular embodiment, the prophylactic or therapeutic agent of the invention is administered intramuscularly, intravenously, intratumorally, orally, intranasally, pulmonary or subcutaneously. The prophylactic or therapeutic agent can be administered by any convenient route, e.g., by infusion or bolus injection, absorbed through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and can be administered with other bioactive agents. Systemic or local administration may be performed.
In one particular embodiment, it is desired to administer the pharmaceutical compositions of the present invention topically to an area in need of treatment, which can be accomplished by, for example, but not limited to, topical injection, by injection, or with the aid of an implant that is a porous or non-porous material that includes a membrane and a matrix, such as a salivary elastic membrane, a polymer, a fibrous matrix (e.g., TISSUE L), or a collagen matrix.
In another embodiment, the pharmaceutical composition of the invention may be delivered in the form of a Controlled or sustained Release system, in one embodiment, Controlled or sustained Release may be achieved using a pump (see L anger, supra; Sefton,1987, CRC crit. Ref. biomed. Eng.14: 20; Buchwald et al, 1980, Surgery 88: 507; Saudek et al, 1989, N.Engl. J. Med.321: 574.) in another embodiment, a polymeric material may be used to achieve Controlled or sustained Release of the therapy of the invention (see, for example, Medical Applications of Controlled Release, L anger and Wise (eds.), Pres, Boca Raca, Fla. (1974); Controlled Release Biosafety, Drugproduct, Deg, Polelabil, Polyacrylamide, Polyvinylacetate, polyethylene acrylate, polyethylene glycol.
A controlled Release system is discussed in the review of L anger (1990, Science 249:1527-1533) the Sustained Release formulation comprising one or more therapeutic agents of the present invention can be produced using any technique known to those skilled in the art, see, for example, U.S. Pat. No.4,526,938, PCT publication No. WO 91/05548, PCT publication No. WO 96/20698, Ning et al 1996, "Integrated Radiology of Human Colon Cancer Xenorograft Using a Sustanated-Release Gel," Radiology & Oncology 39:179-189, Song et al 1995, "organism medical 34. under Targeting of L-cloning-circulation Emulsions," PDAjournal of biological Science & Technology 50:372, control et al 1997 "see, biological samples for example # 94.22 and" biological filtration of biological samples ". 24," these references ".
In a particular embodiment, where the composition of the invention is a nucleic acid encoding a prophylactic or therapeutic agent, the nucleic acid may be administered in vivo to facilitate expression of the prophylactic or therapeutic agent encoded therein by constructing the nucleic acid as part of a suitable nucleic acid expression vector and administering it to bring the nucleic acid into the cell (e.g., by using a retroviral vector) (e.g., see U.S. Pat. No.4,980,286), or by direct injection or using microprojectile bombardment (e.g., gene gun; Biolistic, Dupont), or coated with a lipid or cell surface receptor or transfection agent, or by use in conjunction with a homeobox-shaped peptide known to enter the nucleus (e.g., see Joliot et al, 1991, Proc. Natl. Acad. Sci. USA 88: 4-1868). Alternatively, the nucleic acid may be introduced into the cell and incorporated into the host cell DNA for expression by homologous recombination.
The pharmaceutical compositions of the present invention are formulated to be compatible with their intended route of administration. Examples of routes of administration include, but are not limited to, parenteral, e.g., intravenous, intradermal, subcutaneous, oral, intranasal (e.g., inhalation), transdermal (e.g., topical), transmucosal, and rectal administration. In a particular embodiment, the composition is formulated into a pharmaceutical composition suitable for intravenous, subcutaneous, intramuscular, oral, intranasal or topical administration to a human according to conventional procedures. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. If necessary, the composition may also include a solubilizing agent and a local anesthetic (e.g., lignin) to reduce pain at the injection site.
If the compositions of the present invention are to be administered topically, the compositions may be formulated as ointments, creams, transdermal patches, lotions, gels, shampoos, sprays, aerosols, solutions, emulsions, or other forms well known to those skilled in the art. See, for example, the summary of pharmaceutical sciences and pharmaceutical dosage forms of Remington, 19 th edition, Mack pub. Co., Easton, Pa. (1995). For non-sprayable topical dosage forms, viscous to semi-solid or solid forms containing a carrier or one or more excipients compatible with topical application and having a dynamic viscosity preferably greater than water are typically used. Suitable formulations include, but are not limited to, solutions, suspensions, emulsions, creams, ointments, powders, ini's, salves, and the like, which may be sterilized or mixed or admixed with adjuvants (e.g., preservatives, stabilizers, wetting agents, buffers, or salts) to affect various properties, such as osmotic pressure, if desired. Other suitable topical dosage forms include sprayable aerosols wherein the active ingredient, preferably in combination with a solid or liquid inert carrier, is preferably packaged in admixture with a pressurized volatile substance (e.g., a gaseous propellant such as freon) or in squeeze bottles. Humectants can also be added to pharmaceutical compositions and dosage forms, if desired. Examples of other such feedstocks are known in the art.
If the method of the invention comprises intranasal administration of the composition, the composition may be formulated in the form of an aerosol, spray, mist or drops. In particular, the prophylactic or therapeutic agents for use according to the present invention may be conveniently delivered in aerosol form from pressurized packs or a nebulizer, with the use of a suitable propellant (e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas). In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges (e.g., of gelatin) for use in an inhaler may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
If the methods of the present invention include oral administration, the compositions may be formulated orally in the form of tablets, capsules, cachets, gel caps, solutions, suspensions, and the like. Tablets or capsules may be prepared by conventional means together with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinized corn starch, polyvinylpyrrolidone or hydroxypropylmethyl cellulose), fillers (e.g. lactose, microcrystalline cellulose or dibasic calcium phosphate), lubricants (e.g. magnesium stearate, talc or silicon dioxide), disintegrants (e.g. potato starch or sodium starch glycolate) or wetting agents (e.g. sodium lauryl sulfate). The tablets may be coated by methods known in the art. Liquid preparations for oral administration may take the form of, but are not limited to, solutions, syrups or suspensions, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared in conventional manner together with pharmaceutically acceptable additives such as suspending agents (for example, sorbitol syrup, cellulose derivatives or hydrogenated edible fats), emulsifying agents (for example, lecithin or acacia), non-aqueous vehicles (for example, almond oil, oily esters, ethanol or fractionated vegetable oils) and preservatives (for example, methyl or propyl p-hydroxybenzoates or sorbic acid). The formulations may also suitably contain buffer salts, flavouring agents, colouring agents and sweetening agents. Formulations for oral administration may be suitably formulated for sustained, controlled or sustained release of the prophylactic or therapeutic agent.
The methods of the invention may include pulmonary administration, for example by use of an inhaler or nebulizer, with concomitant formulation with an aerosol. See, for example, U.S. patent nos.6,019,968, 5,985,320, 5,985,309, 5,934,272, 5,874,064, 5,855,913, 5,290,540, and 4,880,078; and PCT publication nos. WO92/19244, WO 97/32572, WO 97/44013, WO 98/31346 and WO 99/66903, all of which are incorporated herein by reference in their entirety. In a particular embodiment, the antibody, combination therapy and/or composition of the invention is administered using the Alkermes AIR pulmonary drug delivery technology (Alkermes, inc., Cambridge, Mass.).
The methods of the invention may include administration of compositions formulated for parenteral administration by injection (e.g., by bolus injection or continuous infusion). Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
The methods of the invention may further comprise administering a composition formulated as a depot formulation. Such long acting formulations may be administered by implantation (e.g., subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compositions may be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins or as sparingly soluble derivatives (e.g., as a sparingly soluble salt).
The methods of the invention comprise the administration of a composition configured as a mesoscopic or saline dosage form. Pharmaceutically acceptable salts include salts with anions and with cations, for example, anions derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, and the like, for example, cations derived from sodium, potassium, ammonium, calcium, ferric hydroxide, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
Typically, the components of the composition are provided separately or mixed together in unit dosage form, e.g., as a dry lyophilized powder or as an anhydrous concentrate in a closed container, e.g., in an ampoule or sachet, to indicate the amount of active agent. Where the mode of administration is infusion, the composition can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the mode of administration is by injection, an ampoule of sterile water for injection or saline may be provided so that the ingredients may be mixed prior to administration.
In particular, the invention also provides packaging one or more prophylactic or therapeutic agents or pharmaceutical compositions of the invention in a hermetically sealed container, such as an ampoule or sachet, which indicates the amount of the agent. In one embodiment, one or more prophylactic or therapeutic agents or pharmaceutical compositions of the invention are provided in a sealed container as a dry sterile lyophilized powder or anhydrous concentrate and can be reconstituted (e.g., with water or saline) to an appropriate concentration for administration to a subject. Preferably, one or more prophylactic or therapeutic agents or pharmaceutical compositions of the invention are provided in a unit dose of at least 5mg, more preferably at least 10mg, at least 15mg, at least 25mg, at least 35mg, at least 45mg, at least 50mg, at least 75mg or at least 100mg in a closed container in the form of a dry sterile lyophilized powder. The lyophilized prophylactic or therapeutic agent or pharmaceutical composition of the present invention should be stored between 2 ℃ and 8 ℃. The prophylactic or therapeutic agent of the invention or the pharmaceutical composition of the invention should be added to its original container and should be administered within 1 week of reconstitution, preferably within 5 days, 72 hours, 48 hours, 24 hours, 12 hours, 6 hours, 5 hours, 3 hours or 1 hour thereafter. In an alternative embodiment, one or more prophylactic or therapeutic agents or pharmaceutical compositions of the invention are provided in liquid form in a sealed container to indicate the amount and concentration of the agent. Preferably, the liquid dosage form of the administration composition is provided in a sealed container of at least 0.25mg/ml, more preferably in a sealed container of at least 0.5mg/ml, at least 1mg/ml, at least 2.5mg/ml, at least 5mg/ml, at least 8mg/ml, at least 10mg/ml, at least 15mg/ml, at least 25mg/ml, at least 50mg/ml, at least 75mg/ml or at least 100 mg/ml. The liquid dosage form should be stored in its original container at between 2 ℃ and 8 ℃.
Preferably, the antibody or antibody portion of the invention will be prepared as an injection containing 0.1-250mg/ml of the antibody, preferably the injection solution may consist of a liquid or lyophilized formulation in a flint or amber vial, ampoule or pre-filled syringe, the buffer may be L-histidine (1-50mM), most preferably 5-10mM, pH 5.0 to 7.0 (most preferably pH 6.0), other suitable buffers including but not limited to sodium succinate, sodium citrate, sodium phosphate or potassium phosphate, sodium chloride may be at a concentration of 0-300mM (most preferably 150mM for a liquid formulation) to improve the toxicity of the solution, for lyophilized formulations, cryoprotectants may be included, primarily 0-10% sucrose (most preferably 0.5-1.0%) for cryoprotectants, other suitable cryoprotectants including trehalose and lactose for lyophilized formulations may include bulking agents, primarily 1-10% mannitol (most preferably 2-4%) for a liquid and stabilizing agent may be used with a liquid and stabilizing agent, and for use as a pharmaceutical composition for parenteral administration with a hyaluronic acid addition of a therapeutic agent, including as a polysorbate 0.10% increasing agent, preferably for parenteral administration of a pharmaceutical composition, e.g. polysorbate 20010% of a pharmaceutical composition, which may also include as a polysorbate-sorbitol, a parenteral adjuvant, preferably a topical adjuvant, for parenteral injection, and/or a pharmaceutical formulation for parenteral injection having an additional bioavailability of an additional suitable for use of a pharmaceutical composition including for increasing the therapeutic agent, including for parenteral protein, e.g. a pharmaceutical composition including a polysorbate, e.g. a topical formulation for parenteral injection having an additional bioavailability of a therapeutic effect, including a topical formulation including a polysorbate, e.g. No. 5-10% sorbitol, No. 5-10, No. 5-10% sorbitol, No. 5-10, No.5 for parenteral injection.
The compositions of the present invention may be in a variety of dosage forms. These include, for example, liquid, semi-solid, and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes, and suppositories. The preferred dosage form depends on the intended mode of administration and therapeutic application. Typical preferred compositions are in the form of injectable or infusible solutions, such as compositions similar to those used for passive immunization of humans with other antibodies. Preferred modes of administration are parenteral (e.g. intravenous, subcutaneous, intraperitoneal, intramuscular). In a preferred embodiment, the antibody is administered by intravenous infusion or injection in another preferred embodiment, the antibody is administered by intramuscular or subcutaneous injection
Therapeutic compositions must generally be sterile and stable under the conditions of manufacture and storage. The compositions may be formulated as solutions, microemulsions, dispersions, liposomes or other ordered structures suitable for high drug concentrations. Sterile injectable solutions can be prepared by incorporating the active compound (i.e., the antibody or antibody portion) in the required amount in an appropriate solvent with one or more of the ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile lyophilized powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and spray drying which yields a powder of the active ingredient and any additional desired ingredient from a previously sterile-filtered solution thereof. Proper fluidity of the solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, such as monostearate salts and gelatin.
Although the preferred route/mode of administration for many therapeutic applications is subcutaneous injection, intravenous injection or infusion, the antibodies and antibody portions of the invention can be administered by a variety of methods known in the art. One skilled in the art will appreciate that the route and/or mode of administration will vary depending on the desired result. In certain embodiments, the active compounds can be prepared with carriers that protect the compound from rapid release, such as controlled release formulations, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid may be used. Many methods of preparing such formulations have been patented or are generally known to those skilled in the art. See, for example, Sustained and Controlled Release Drug Delivery Systems, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.
In certain embodiments, the antibodies or antibody portions of the invention may be administered orally, e.g., with an inert diluent or an absorbable edible carrier. The compound (and other ingredients, if desired) can also be encapsulated in hard or soft shell gelatin capsules, compressed into tablets, or incorporated directly into the diet of a subject. For oral therapeutic administration, the compounds may be combined with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, antiageing drugs, suspensions, syrups, wafers, and the like. In order to administer a compound of the invention by means other than parenteral administration, it may be desirable to include the compound in, or co-administer it with, a material that prevents its inactivation.
In other embodiments, the antibodies or antibody moieties of the invention may be conjugated to a polymer-based substance such that the polymer-based substance can impart to the antibodies or antibody moieties of the invention sufficient size to benefit from the antibodies or antibody moieties of the invention with enhanced permeability and retention effects (EPR effects) (see also PCT publication No. wo2006/042146a2 and U.S. patent publication nos.2004/0028687a1, 2009/0285757a1 and 2011/0217363a1, and U.S. patent No.7,695,719), all of which are incorporated herein by reference in their entirety.
In certain embodiments, the antibody or fragment thereof is linked to a carrier known in the art to increase half-life. Such carriers include, but are not limited to, Fc domains, polyethylene glycols, and dextrans. Such vectors are described in the following patents: for example, U.S. patent serial No.09/428,082 and published PCT application No. wo 99/25044, both of which are incorporated herein by reference.
In a particular embodiment, a nucleic acid sequence comprising a nucleotide sequence encoding an antibody of the invention or another prophylactic or therapeutic agent of the invention is administered by gene therapy to treat, prevent, control or ameliorate a disease or one or more symptoms thereof. Gene therapy refers to treatment by administering an expressed or expressible nucleic acid to a subject. In this embodiment of the invention, the nucleic acid produces the antibody of the invention encoded thereby or a prophylactic or therapeutic agent that mediates a prophylactic or therapeutic effect.
General reviews on Gene therapy methods are available in the art, see Goldspire et al, 1993, Clinical Pharmacy 12:488-505, Wu and Wu, 1991, Biotherapy 3:87-95, Tolstoshev 1993, Ann.Rev.Pharmacol.Toxicol.32:573-596, Mulligan Science 260:926-932(1993), and Morgan and Anderson, 1993, Ann.Rev.biochem.62:191-217, May 1993, TIBTECH 11(5): 155-215. well known methods in the field of recombinant DNA technology, as described in Aurea et al (documents), Inc. molecular Biology, Willian & William & 1990, the methods described in detail in U.S. Stodserves et al (handbook et al, USA), the methods of treatment are incorporated by the teachings of Golddserv et al, Inc., handbook et al, (1990, 19852, Inc., Prekusank.A.52).
Antibody production
The antibodies of the invention can be produced by any of a variety of techniques known in the art. For example, expression from a host cell is by standard techniques, wherein expression vectors encoding the heavy and light chains are transfected into the host cell. The term "transfection" of various forms is intended to cover the usually used to introduce exogenous DNA into prokaryotic or eukaryotic host cells in a variety of techniques, such as electroporation, calcium phosphate precipitation, DEAE-dextran transfection. Although it is possible to express the antibodies of the invention in prokaryotic or eukaryotic host cells, expression of the antibodies in eukaryotic cells is preferred, and most preferred in mammalian host cells, because such eukaryotic cells (particularly mammalian cells) are more likely than prokaryotic cells to assemble and secrete properly folded and immunologically active antibodies.
Exemplary nucleic acids of the invention are shown in table 17.
Exemplary mammalian host cells for expressing recombinant antibodies of the invention include Chinese hamster ovary (CHO cells) (including DHFR-CHO cells such as Urlaub and Chasin, (1980) Proc. Natl. Acad. Sci. USA 77:4216-4220, used with DHFR selectable markers (e.g., as described in R.J. Kaufman and P.A. Sharp (1982) mol. biol.159: 601-621), NS0 myeloma cells, COS cells, and SP2 cells.
The host cell may also be used to produce functional antibody fragments, such as Fab fragments or scFv molecules. It will be appreciated that variations of the above process are within the scope of the invention. For example, it may be desirable to transfect a host cell with DNA encoding a functional fragment of the light and/or heavy chain of an antibody of the invention. Recombinant DNA techniques can also be used to remove some or all of the DNA encoding one or both of the light or heavy chains that are not necessary for binding to the antigen of interest. Molecules expressed by such truncated DNA molecules are also included in the antibodies of the invention. Alternatively, bifunctional antibodies may be produced in which one heavy and one light chain is an antibody of the invention, and the other heavy and light chains are antibodies specific for an antigen other than the antigen of interest by cross-linking the antibody of the invention to a second antibody by standard chemical cross-linking methods.
In a preferred system for recombinant expression of the antibodies of the invention, or antigen-binding portions thereof, recombinant expression vectors encoding the antibody heavy and light chains are introduced into DHFR-CHO cells by calcium phosphate-mediated transfection.
Another embodiment of the invention provides a glycosylated antibody or an antigen binding portion thereof, wherein the antibody or antigen binding portion thereof comprises one or more carbohydrate residues. The production of nascent proteins in vivo may undergo further processing, known as post-translational modification. Specifically, sugar (glycosyl) residues can be added enzymatically, a process known as glycosylation. The resulting protein with covalently attached oligosaccharide side chains is called a glycosylated protein or glycoprotein. Antibodies are glycoproteins that have one or more carbohydrate residues in the Fc domain as well as in the variable domain. Carbohydrate residues in the Fc domain have a significant effect on the effector function of the Fc domain with minimal effect on antigen binding or antibody half-life (r.jefferis, biotechnol. prog.21(2005), pp.11-16). In contrast, glycosylation of the variable domain may have an effect on the antigen binding activity of the antibody. Glycosylation in the variable domain may have a negative effect on antibody binding affinity, possibly due to steric hindrance (Co, M.S. et al, mol.Immunol. (1993)30: 1361. sup. 1367), or lead to an increased affinity for the antigen (Wallick, S.C. et al, exp.Med. (1988)168: 1099. sup. 1109; Wright, A. et al, EMBO J. (1991)10: 2717. sup. 2723).
One aspect of the invention relates to the generation of glycosylation site mutants, wherein the O-or N-linked glycosylation sites of an antibody, or antigen-binding portion thereof, have been mutated. Such mutants can be generated by one skilled in the art using standard well-known techniques. Glycosylation site mutants that retain biological activity but have increased or decreased binding activity are another object of the invention.
In yet another embodiment, the glycosylation of an antibody or antigen binding portion of the invention is modified. For example, non-glycosylated antibodies (i.e., antibodies lacking glycosylation) can be prepared. Glycosylation can be altered, for example, to increase the affinity of an antibody for an antigen. Such carbohydrate modifications can be achieved, for example, by altering one or more glycosylation sites within the antibody sequence. For example, one or more amino acid substitutions can be made that result in the elimination of one or more variable region glycosylation sites, thereby eliminating glycosylation at that site. This glycosylation can increase the affinity of the antibody for the antigen. The process is further described in detail in PCT publication No. WO2003016466a2 and U.S. patent nos.5,714,350 and 6,350,861, all of which are incorporated herein by reference in their entirety.
Additionally or alternatively, modified antibodies of the invention with altered glycosylation patterns can be prepared, such as sub-fucosylated antibodies with reduced amounts of fucosyl residues or antibodies with increased bisecting GlcNAc structure.
Protein glycosylation depends on the amino acid sequence of the protein of interest and the host cell in which the protein is expressed. Different organisms can produce different glycosylases (e.g., glycosyltransferases and glycosidases) and have different substrates (nucleotide sugars) available. Due to these factors, the glycosylation pattern of a protein and the composition of glycosyl residues may vary, depending on the host system in which a particular protein is expressed. Glycosyl residues useful in the present invention can include, but are not limited to, glucose, galactose, mannose, fucose, n-acetylglucosamine, and sialic acid. Preferably, the glycosylated antibody or antigen binding portion thereof comprises glycosyl residues such that the glycosylation pattern is human.
It is known to the person skilled in the art that different glycosylation of proteins may lead to different protein properties. For example, a therapeutic protein that is glycosylated using the yeast endogenous pathway produced in a microbial host, such as yeast, may have reduced efficacy compared to the same protein expressed in a mammalian cell, such as a CHO cell line. Such glycoproteins may also be immunogenic in humans and have a reduced half-life in vivo following administration. Specific receptors in humans and other animals recognize specific glycosyl residues and facilitate rapid clearance of proteins from the bloodstream. Other adverse effects may include changes in protein folding, solubility, sensitivity to proteases, trafficking, transport, compartmentalization, secretion, recognition by other proteins or factors, antigenicity, or allergenicity. Thus, a practitioner may prefer a therapeutic protein having a particular glycosylation composition and pattern, for example, a glycosylation composition and pattern that is the same as or at least similar to that produced in human cells or species-specific cells of the intended subject animal.
Expression of a glycosylated protein different from the host cell may be achieved by genetically modifying the host cell to express the heterologous glycosylase. Using techniques known in the art, practitioners can generate antibodies or antigen-binding portions thereof that exhibit glycosylation of human proteins. For example, yeast strains have been genetically modified to express non-naturally occurring glycosylases such that glycosylated proteins (glycoproteins) produced in these yeast strains exhibit the same protein glycosylation as animal cells, particularly as human cells (U.S. patent nos. 20040018590 and 20020137134, and PCT publication No. WO2005100584 a 2).
In addition to antibodies or antigen-binding portions thereof, the invention also relates to anti-idiotypic (anti-Id) antibodies specific for such antibodies or antigen-binding portions thereof of the invention. An anti-Id antibody is an antibody that recognizes a unique determinant that is normally associated with the antigen binding region of another antibody. anti-Id can be prepared by immunizing an animal with an antibody or antigen-binding portion thereof or a CDR-containing region thereof. The immunized animal will recognize and respond to the idiotypic determinants of the immunizing antibody and produce an anti-Id antibody. The anti-Id antibody may also be used as an "immunogen" to induce an immune response in another animal, thereby producing a so-called anti-Id antibody.
Furthermore, it will be appreciated by those skilled in the art that a library of host cells genetically engineered to express various glycosylation enzymes can be used to express a protein of interest such that the member host cells of the library produce the protein of interest with a variable glycosylation pattern. The practitioner can then select and isolate a protein of interest having a particular novel glycosylation pattern-preferably, a protein having a particular selected novel glycosylation pattern exhibits improved or altered biological properties.
It will be apparent to those skilled in the art that other suitable modifications and variations of the method of the invention described herein are apparent and may be made using suitable equivalents without departing from the scope of the invention or the embodiments disclosed herein. Having now described the invention in detail, it will be more clearly understood by reference to the following examples, which are included merely for purposes of illustration and are not intended to limit the invention.
Any and all journal articles, patent applications, issued patents, and publications disclosed herein
Or other cited references, are incorporated by reference in their respective entireties.
Examples of the invention
Example 1 computational framework for estimation and filtering of immunoglobulin sequences based on RNAseq data from the TCGA database.
The present invention describes a computational framework developed and successfully tested antibody discovery by mining large numbers of Ig CDR3 sequences in samples based on solid tumor RNA sequencing in 1945 in the TCGA databases of glioblastoma multiforme (GBM), lower gliomas (L GG), lung adenocarcinoma (L UAD), squamous cell carcinoma of the lung (L USC), pancreatic adenocarcinoma (PAAD), and cutaneous melanoma (SKCM). surprisingly, synthetic antibodies based on selected high abundance CDR3 sequences from patients L UAD bind to multiple lung cancer samples and are cross-reactive with other types of cancer but importantly have very little cross-reaction with normal tissue.
Recent studies by us and others have shown that the TCGA RNAseq database captures the characteristics of the T cell pool within the tumor (3). However, similar analysis has not been performed on antibody libraries. To fill this major gap, a platform was developed that not only describes the status of antibody responses, but also identifies specific sequences that may be useful in cancer therapy and diagnosis, as shown in fig. 1A.
First, reads are aligned to the B cell receptor reference V, D, J and C genes, and then gene signature sequences (called clone sequences) are extracted from the aligned reads, as shown in fig. 1B, identifying a large number of Ig transcripts in all six cancer types analyzed, wherein the L USC and L UAD transcriptomes contain significantly more Ig transcriptomes, next, clonotypes are assembled for the clone sequences (based on the CDR3 regions) after the core clonotypes are constructed, a mapping is performed that processes the delayed records in the previous step in order to rescue quantitative information from the low-mass reads, clustering is performed after the clonotypes are assembled by the original assembler and mapper, connecting the low-abundance clonotypes to the high-abundance, significantly similar clonotypes, as shown in fig. 1B, although the BCR clonotypes of L USC and L UAD transcriptomes are more abundant, a large number of clonotypes are found in all six cancer types, and thus, the number of millions of aligned heavy chain reads (igeq) in the heavy chain reads are used as a measure of the number of heavy chain assembled Ig transcripts per million of millions of igpm in all six cancer types.
The analysis of B cell clonality reveals substantial differences in B cell clonality between different patients between different tumor populations (fig. 1C), thus providing valuable guidance for identifying patient samples with highly amplified BCR clones, the final step is to align the cloned sequences with reference VD, J, and C genes to reconstruct the alignment of the cloned sequences and add information to them, such as amino acid sequences and related variable (V) and linking (J) genes, considering the main abundances observed in BCR density and clonality in TCGA L UAD populations, the selection of immunoglobulin transcripts relative to the abundance of total eq for the first sample ranking of the igr clones for verification of the abundance of the first sample for the igr clone abundance using the IgH sequence alignment chart for verification of the IgH sequence score in ige 3, the CDR score chart for the first sample of IgH 369 igg gene alignment chart for verification of the CDR sequence score using the IgH 75, CDR 75, and CDR 75 h score chart for the test results of the CDR sequence alignment chart, the results of the IgH 369 and CDR 75 h.
Co-enrichment of the H and L chain CDR3 suggests that they are likely to pair, as suggested by parallel studies in T cells (4) however, it is not possible to determine pairing by frequency alone (5). despite this, since the goal is to recognize cancer-reactive antibodies rather than to describe endogenous antibody responses, 3H chain and 6L chain were randomly combined in pairs and tested to determine whether immunoglobulins were expressed from these pairs.these antibodies were linked to mouse IgG2a heavy and k light chains to facilitate future studies of human tissues that may have endogenous human IgG.As shown in FIG. 1G, of the 18 combinations, 13 combinations produced significant levels of antibody in transient transfections and therefore provided a valuable tool for assessing antibody specificity.
Tables 1-6 show the top 100 heavy chains and the top 100 light chains selected from the top three patients in the TCGA database.
Tables 7-16 show the first 50 heavy chains and the first 50 light chains selected from each tumor sample of the Adaptive Biotechnologies database.
Example 2 antibody repertoire of 13 recombinant antibodies generated by random pairing of 3 heavy and 6 light chains bound to L USCs and L UAD tissues.
To determine whether de novo assembled antibodies bound to cancer tissue, these 13 antibodies were paired and immunofluorescent with frozen tissue of L USC and L UAD. the assembled antibodies were tested using goat anti-mouse second step reagents as shown in fig. 5, the antibody library showed superior binding to L USC and L UAD. when the antibodies were tested alone, 9/13 showed clear binding to L UAD. of these, 6 also reacted with L USC (fig. 2A). H2L 7 was selected for further testing because it has a unique staining pattern and has broad cross reactivity with all five lung cancer samples, including two L UAD tumor tissues and 3L USC tumor tissues in frozen sections.
Example 3H 2L 7 binds to a variety of malignant tissues, but has limited binding to normal tissues.
H2L 7 is characterized by its binding to normal and different types of cancer tissue after frozen tissue microarray examination of normal tissue, H2L 7 was unresponsive to most of the normal tissues tested (fig. 3A) although some binding to intracellular components or extracellular matrix was found in pancreas, spleen, parotid gland and testis, no definitive cell surface staining was found for any normal tissue in contrast, H2L 7 was broadly reactive to the 9/11 types of cancer tissues tested, including colon adenocarcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, ovarian adenocarcinoma, soft tissue cytoma, liver hepatocellular carcinoma, testicular seminoma, lung adenocarcinoma and lung squamous carcinoma (fig. 3B) in addition, H2L 7 was tested against L USC TMA containing paired malignant and normal adjacent tissues the staining results showed that H2L 7 binds strongly to 100% of L USC but only to 25% of adjacent benign tissues (fig. 3C and 3D).
Example 4 recombinant antibodies derived from the target genomic sequence of L UAD (sample 463) whereas L USC (sample 427) showed limited cross-reactivity.
As an alternative method, genomic DNA in frozen tissues of lung cancer samples WAs extracted and BCR sequencing WAs performed using its facilitated sequencing and analysis method (IMMUNOSEQ Assay) (Adaptive biotechnology, Seattle, WA). This method identified 3548 heavy and 5913 light chain heavy and light chain sequences for the BCR in sample 463, and 5901 heavy and 10679 light chain sequences in sample 427. In each case, the two most abundant heavy and light chain clones were selected (FIG. 4A) and aligned to the IMGT BCR reference sequence using the V-QUEST tool. The alignment to the highest score (S) was recorded. For each rearranged sequence, the information on VDJ gene usage indicated by BCR sequencing results was verified by IMGT alignment results. The rearranged sequences were then extended to the full-length immunoglobulin sequences using the germline sequences of the validated V and J genes.
The heavy and light chains from the same sample were paired homogenously and expressed in 293T cells by transient transfection as shown in figure 4B, all eight of these combinations resulted in significant levels of antibody production, antibodies H5L and H6L 13 were selected and tested against 2L USC and 3L UAD samples, including the samples from which the antibody sequences were assembled, as shown in figure 4C, H6L showed strong binding to the cancer tissue from which the antibodies were obtained, it was interesting that H5L 12 showed not only binding to the L UAD tissue sample obtained from it, but also cross-reactivity to another L UAD tested, but no cross-reactivity to the 3 tested L USC samples.
The data presented herein demonstrate that it is possible to identify large numbers of immunoglobulin sequences based on de novo assembly of transcriptomes and targeted sequencing of genomic DNA isolated from clinical samples, and selected examples show exclusive specificity and broad cross-reactivity to cancer tissues. Several types of organization are worth considering.
First, because antibodies are assembled based on somatic and germline sequences, and because pairing of heavy and light chains is based on random combinations, the identified antibodies may not represent an endogenous antibody response to cancer. Thus, antibody discovery using the methods described herein may be better than describing endogenous antibody responses. Recent studies have shown that single cell based sequences can describe antibody responses (6).
In addition, the present invention provides methods for identifying antigens that are recognized by antibodies, such as H2L 7, that are capable of being used in the treatment of cancer, and that allow for the identification of antigens that are recognized by antibodies.
Third, it should be noted that although the depth and length of the RNAseq data in the TCGA database does not allow the assembly of full-length Ig sequences, the length and depth can be increased to obtain such sequences, as can some recent databases. It should be noted that the sequences reconstructed from CDR3 appear to produce broadly reactive antibodies, while the sequences reconstructed from targeted sequencing data include some somatic mutations and are therefore highly specific. These data motivate the possibility that somatic mutations that increase antibody affinity may also reduce cross-reactivity. If this hypothesis can be confirmed by further studies, antibody sequences reconstructed only from the CDR3 may be of intrinsic value for cancer diagnosis.
Taken together, the ability to generate antibodies with broad cross-reactivity or high specificity to cancer samples suggests that the platform described herein may allow the identification of fully human antibodies for the treatment and/or diagnosis of human cancer. For diagnosis, these antibodies can be further modified by mutagenesis to further eliminate their cross-reactivity with normal tissues. For therapeutic development, antibodies can be further modified to enhance effector function by Fc optimization (7), antibody-drug binding (8), bispecific antibodies (9), and chimeric antigen receptors (10).
Example 5 Process
Examples 1 to 4 utilize, but are not limited to, the following methods.
Accessing and analyzing TCGA data sets
BAM-formatted primary solid tumor RNA sequencing Data for 6 cancer types (glioblastoma multiforme, N: 154; low grade glioma, N: 512; lung adenocarcinoma, N: 525; lung squamous carcinoma, N: 474; pancreatic adenocarcinoma, N: 177; skin melanoma, N: 103) were obtained from the NCI Genomic Data Commons portal (https:// portal.gdc.cancer.gov /). First, all files are extracted into the fastq file using samtools (11) fastq function with-O settings. The reads were aligned to the reference V, D, J and C genes of the human B cell receptor by using the MIXCR (12) alignment function. Two rounds of contig assembly were then performed using the MIXCR rescue function in RNAseq mode. BCR CDR3 clones were assembled by using the MIXCR function based on aligned contigs. Further fragment usage and correlation analyses were performed on the BCR track using VDJtools (13) software and R software (https:// www.r-project. org /).
Calculation of IgH clonality
The IgH clonality is defined as the 1-Pielou homogeneity and effectively rearranged according to the following formula:
where Ci is the clone score of rearrangement i and N is the total number of rearrangements. Calculation of IgH clonality was achieved in the R software (https:// www.r-project. org /) using the vegetarian food drawer software package (14).
Genomic DNA extraction and BCR library sequencing
2 cases L UAD cancer samples (samples 463 and 429) and 3 cases L USC cancer samples (sample 427, sample 840, sample 350) were selected for DNA extraction using TRIZO L reagent (15596026, lot 86105, ThermoFisher Scientific) according to the manufacturer's instructions.
Recombinant antibody production
Each heavy chain was co-transfected with each light chain at a 1:1 ratio into HEK293T (CR L-11268, ATCC) using PO L YFECT Transfection Reagent (Qiagen, 1015586, batch 154044326) or L ipofectamine 3000(Invitrogen, L3000-015, batch 1811506) HEK293T cells were grown in DMEM (L ife Technologies, 11965-15142) supplemented with 10% fetal bovine serum (GE Healthcare L ife Sciences, SH30910.03) and 10ug/ml penicillin/streptomycin (GEHealthcare L ife Sciences, 0-122) three days after Transfection, supernatants were collected and the concentration of recombinant antibody expressed by the sandwich E L ISA was assessed using known standards.
Tissue, tissue microarray and immunogenic fluorescence assay
Frozen lung tumor samples were purchased from proteogenx (Inglewood, CA) frozen Tissue was embedded in a frozen mould (Tissue-Tek, 4728) together with o.c. t compound (Tissue-Tek, 4583) and cut into 5 micron sections frozen multi-Tissue microarrays (FMC402a) and lung Tissue microarrays (F L C320) were purchased from US Biomax, Inc (Rockville, MD) frozen Tissue sections and TMA were thawed at room temperature for 10-20 minutes and washed in PBS 3 times frozen sections were fixed in 4% formaldehyde at room temperature for 10 minutes, then sections were washed in PBS 3 times for 5 minutes each, then sections were incubated in blocking solution (5% normal goat serum in PBS) for 1 hour — sections were incubated with each recombinant antibody in complete DMEM at room temperature or 4 ℃ for 2 hours or 4 ℃ for 3 times, as above in PBS 3 times, and incubated with moist Tissue in blocking solution (thermo PBS) with Pro buffered saline, with anti-fisher P3 times, with Pro buffered saline, and with blocking buffer (3) in Pro buffered saline, e.g. 3 times buffered saline, with fluorescence buffered saline, e.g. 3.
Biometrics
The specific tests used to analyze each set of experiments are shown in the legend. Data were analyzed using a fisher exact test tabulation. Statistical calculations were performed using GraphPad Prism Software (GraphPad Software, San Diego, California).
Reference to the literature
1.Adams,G.P.&Weiner,L.M.Monoclonal antibody therapy ofcancer.Nat.Biotechnol.23,1147–1157(2005).
2.Weiner,L.,Murray,J.&Shuptrine,C.Antibody-based immunotherapy ofcancer:New insights,new targets.Cell 148,1081–1084(2012).
3.Li,B.et al.Landscape of tumor-infiltrating T cell repertoire ofhuman cancers.Nat.Genet.48,725-732(2016).
4.Linnemann,C.et al.Technical Reports High-throughput identificationof antigen-specific TCRs by TCR gene capture.Nat.Med.19,1534-1541(2013).
5.Dekosky,B.J.et al.High-throughput sequencing of the paired humanimmunoglobulin heavy and light chain repertoire.Nat.Biotechnol.31,166-199(2013).
6.Georgiou,G.et al.The promise and challenge of high-throughputsequencing of the antibody repertoire.Nat.Biotechnol.32,158-168(2014).
7.P.,Jean-Mairet,J.,Moudry,R.,Amstutz,H.&Bailey,J.E.Engineeredglycoforms of an antineuroblastoma IgG1 with optimized antibody-dependentcellular cytotoxic activity.Nat.Biotechnol.17,176–80(1999).
8.Hurwitz,E.,Arnon,R.,Sahar,E.&Danon,Y.a Conjugate of Adriamycin andMonoclonal Antibodies ToAntigen Inhibits Human Neuroblastoma Cells inVitro.Ann.N.Y.Acad.Sci.417,125–136(1983).
9.Merchant,A.M.et al.An efficient route to human bispecificIgG.Nat.Biotechnol.16,677-681(1998).
10.Eshhar,Z.,Waks,T.,Gross,G.&Schindler,D.G.Specific activation andtargeting of cytotoxic lymphocytes through chimeric single chains consistingof antibody-binding domains and the gamma or zeta subunits of theimmunoglobulin and T-cell receptors.Proc.Natl.Acad.Sci.90,720-724(1993).
11.Li,H.et al.The Sequence Alignment/Map format andSAMtools.Bioinformatics 25,2078–2079(2009).
12.Bolotin,D.A.et al.MiXCR:software for comprehensive adaptiveimmunity profiling.Nat.Methods 12,380–381(2015).
13.Shugay,M.et al.VDJtools:Unifying Post-analysis of T Cell ReceptorRepertoires.PLoS Comput.Biol.11,1-16(2015).
Reuben, A.et al.TCR recombinant Intratum or specificity in L transformed L un induced adipogens an Association with Predicted Neoantigenic specificity and Postsurgical Recurrence cancer Discov.10, 1088-1097 (2017). Table 1-first 100 heavy chain CDRs 3 from patient 1
TABLE 2 first 100 heavy chain CDRs 3 from patient 1
TABLE 3 first 100 heavy chain CDRs 3 from patient 2
TABLE 4 first 100 heavy chain CDRs 3 from patient 2
TABLE 5 first 100 heavy chain CDRs 3 from patient 3
TABLE 6 first 100 heavy chain CDRs 3 from patient 3
TABLE 7-sample 350 (heavy chain)
TABLE 8-sample 350 (light chain)
TABLE 9-sample 427 (heavy chain)
TABLE 10 sample 427 (light chain)
TABLE 11 sample 429 (heavy chain)
TABLE 12 sample 429 (light chain)
TABLE 13-sample 463 (heavy chain)
TABLE 14-sample 463 (light chain)
TABLE 15-sample 840 (heavy chain)
TABLE 16-sample 840 (light chain)
TABLE 17 antibody sequences
Claims (57)
1. A method of identifying one or more nucleic acid sequences encoding an antibody or antibody fragment from a transcriptome of a subject, the method comprising:
a. screening the transcriptome of the subject for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences;
b. calculating a clonality score corresponding to one or more of the nucleic acid sequences in each of the first and second sets of nucleic acid sequences;
c. separating the nucleic acid sequences into the first set of nucleic acid sequences and the second set of nucleic acid sequences based on the clonality score.
2. The method of claim 1, further comprising the steps of: (d) after performing the step of classifying, identifying from the first set of nucleic acid sequences a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable strand.
3. The method of claim 2, further comprising repeating the steps of identifying a nucleic acid sequence encoding at least one CDR of the variable chain and editing the plurality of CDR sequences.
4. The method of claim 2, further comprising:
e. screening the transcriptomes of a series of control subjects for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences;
f. calculating a clonality score corresponding to one or more of the nucleic acid sequences in each of the first and second sets of nucleic acid sequences;
g. dividing the nucleic acid sequences into the first set of nucleic acid sequences and the second set of nucleic acid sequences based on the clonality score;
h. obtaining a set of abundantly expressed nucleic acid sequences encoding antibody fragments from the series of control subjects and comparing the nucleic acid sequences of the first set from the series of control subjects to the first set of nucleic acid sequences from the subjects;
wherein steps (e) to (h) are performed before, simultaneously with or after steps (a) to (c);
and wherein said step of identifying from the subject's transcriptome a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable strand is based on said step of comparing sets of abundantly expressed nucleic acid sequences from step (h).
5. The method of any one of claims 1 to 4, wherein the first set of abundantly expressed nucleic acid sequences from the subject encodes one or a combination of antibody fragments selected from: an Fc portion of an antibody, a single chain variable fragment of an antibody (ScFv), an Fv portion of an antibody, an Fab fragment of an antibody, an F (ab')2 fragment of an antibody, an Fd fragment of an antibody, an IgG-like fragment of an antibody, a variable chain of an antibody, and a constant region of an antibody.
6. The method of any one of claims 1 to 5, wherein the first set of abundantly expressed nucleic acid sequences from the subject encodes one or a combination of variable heavy and/or variable light portions of the antibody.
7. The method of any one of claims 1 to 6, wherein the screening step comprises screening for nucleic acid sequences encoding antibody fragments of one or more B Cell Receptor (BCR) sequences, and the step of calculating the clonality score of the antibody is determined at least in part by the formula:
where Ci is the clone score of rearrangement i and N is the total number of rearrangements.
8. The method of any one of claims 1 to 7, wherein said screening the nucleic acid sequences encoding one or more antibody fragments in the transcriptome of a series of control subjects comprises performing the FASTQ, MIXCR and vdjsols functions on the transcriptome data.
9. The method of any one of claims 1 to 8, wherein said screening the transcriptome of said subject for nucleic acid sequences encoding one or more antibody fragments comprises performing an alignment of cloned sequences.
10. The method of claim 9, wherein the alignment of cloned sequences comprises performing an immunizing SEQ function.
11. The method of any one of claims 1 to 10, wherein the sample is a tissue sample from a subject having or suspected of having a hyperproliferative disease.
12. The method of any one of claims 1 to 10, wherein the sample comprises one or more hyperproliferative cells selected from the following cancers: glioblastoma multiforme, low-grade gliomas, lung adenocarcinomas, lung squamous carcinomas, pancreatic adenocarcinomas and skin cancers.
13. A computer-implemented method for detecting the presence of a nucleic acid sequence encoding an antibody or antibody fragment in a transcriptome of a sample, the method comprising: in a system comprising at least one processor and a memory,
a. screening, by the at least one processor, the transcriptome of the subject for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences;
b. calculating, by the at least one processor, a clonality score corresponding to one or more of the nucleic acid sequences in each of the first and second sets of nucleic acid sequences;
c. separating, by the at least one processor, the nucleic acid sequences into the first set of nucleic acid sequences and the second set of nucleic acid sequences according to the clonality score.
14. The method of claim 13, further comprising the steps of: (d) after performing the step of classifying, identifying from the first set of nucleic acid sequences a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable strand.
15. The method of claim 14, further comprising repeating the steps of identifying a nucleic acid sequence encoding at least one CDR of the variable chain and editing the plurality of CDR sequences.
16. The method of claim 14, further comprising:
e. screening the transcriptomes of a series of control subjects for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences;
f. calculating a clonality score corresponding to one or more of the nucleic acid sequences in each of the first and second sets of nucleic acid sequences;
g. dividing the nucleic acid sequences into the first set of nucleic acid sequences and the second set of nucleic acid sequences based on the clonality score;
h. obtaining a set of abundantly expressed nucleic acid sequences encoding antibody fragments from the series of control subjects and comparing the nucleic acid sequences of the first set from the series of control subjects to the first set of nucleic acid sequences from the subjects;
wherein steps (e) to (h) are performed before, simultaneously with or after steps (a) to (c);
and wherein said step of identifying from the subject's transcriptome a nucleic acid sequence encoding at least one CDR of a variable chain is based on the step of comparing said plurality of sets of abundantly expressed nucleic acid sequences from step (h).
17. The method of any one of claims 13 to 16, wherein the first set of abundantly expressed nucleic acid sequences from the subject encodes one or a combination of antibody fragments selected from: an Fc portion of an antibody, a single chain variable fragment of an antibody (ScFv), an Fv portion of an antibody, an Fab fragment of an antibody, an F (ab')2 fragment of an antibody, an Fd fragment of an antibody, an IgG-like fragment of an antibody, a variable chain of an antibody, and a constant region of an antibody.
18. The method of any one of claims 13 to 17, wherein the first set of abundantly expressed nucleic acid sequences from the subject encodes one or a combination of variable heavy and/or variable light portions of the antibody.
19. The method of any one of claims 13 to 18, wherein the screening step comprises screening for nucleic acid sequences encoding antibody fragments of one or more B Cell Receptor (BCR) sequences, and the step of calculating the clonality score of the antibody is determined at least in part by the formula:
where Ci is the clone score of rearrangement i and N is the total number of rearrangements.
20. The method of any one of claims 16 to 19, wherein the screening the transcriptome of a series of control subjects for nucleic acid sequences encoding one or more antibody fragments comprises performing FASTQ, MIXCR and vdjsols functions on the transcriptome data.
21. The method of any one of claims 13 to 20, wherein said screening the transcriptome of said subject for nucleic acid sequences encoding one or more antibody fragments comprises performing an alignment of cloned sequences.
22. The method of claim 21, wherein the alignment of cloned sequences comprises performing an immunizing SEQ function.
23. The method of any one of claims 13 to 22, wherein the sample is a tissue sample from a subject having or suspected of having a hyperproliferative disease.
24. The method of any one of claims 13 to 23, wherein the sample comprises one or more hyperproliferative cells selected from the following cancers: glioblastoma multiforme, low-grade gliomas, lung adenocarcinomas, lung squamous carcinomas, pancreatic adenocarcinomas and skin cancers.
25. The method of claim 1 or 13, wherein the first set of nucleic acids encoding antibodies or antibody fragments encodes antibodies capable of binding to one or more cells from the sample and/or subject.
26. A method of editing a set of nucleic acid sequences encoding an antibody or antibody fragment from a sample, the method comprising:
(a) obtaining at least one nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of a variable strand from a transcriptome of the subject by the method of any one of claims 1 to 25; and
(b) repeating step (a) until a plurality of nucleic acid sequences encoding the antibody or antibody fragment are aggregated from the sample.
27. A method of designing an antibody or antibody fragment capable of binding a cellular epitope from a sample, the method comprising:
(a) obtaining at least one nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of a variable strand from a transcriptome of the subject by the method of any one of claims 1 to 25; and
(b) repeating step (a) until a plurality of nucleic acid sequences encoding the antibody or antibody fragment are aggregated from the sample;
(c) cloning one or more nucleic acids in a vector or synthesizing the antibody by solid state chemical synthesis; and
if the one or more nucleic acid sequences are cloned into a vector, then (d) the vector is transformed into a host cell, and (e) sufficient time is allowed for the recombinant production of the encoded antibody or antibody fragment by the host cell.
28. A composition comprising an antibody or antibody fragment comprising at least one CDR sequence obtained by performing the method of any one of claims 1 to 25.
29. An antibody library comprising at least one amino acid sequence obtained by performing the method of any one of claims 1 to 27.
30. A non-transitory computer program product encoded on a computer-readable storage medium, the non-transitory computer program product comprising instructions for:
a. screening the transcriptome of the subject for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences;
b. calculating a clonality score corresponding to one or more of the nucleic acid sequences in each of the first and second sets of nucleic acid sequences;
c. separating the nucleic acid sequences into the first set of nucleic acid sequences and the second set of nucleic acid sequences based on the clonality score.
31. The non-transitory computer program product of claim 30, further comprising instructions for: (d) after performing the step of classifying, identifying from the first set of nucleic acid sequences a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable strand.
32. The non-transitory computer program product of claim 31, further comprising instructions for repeating the steps of identifying a nucleic acid sequence encoding at least one CDR of a variable chain and editing a plurality of CDR sequences.
33. The non-transitory computer program product of claim 31, further comprising instructions for:
e. screening the transcriptomes of a series of control subjects for nucleic acid sequences encoding one or more antibody fragments, wherein the nucleic acid sequences encoding one or more antibody fragments comprise a first set of abundantly expressed nucleic acid sequences and a second set of rarely expressed nucleic acid sequences;
f. calculating a clonality score corresponding to one or more of the nucleic acid sequences in each of the first and second sets of nucleic acid sequences;
g. dividing the nucleic acid sequences into the first set of nucleic acid sequences and the second set of nucleic acid sequences based on the clonality score;
h. obtaining a set of abundantly expressed nucleic acid sequences encoding antibody fragments from the series of control subjects and comparing the nucleic acid sequences of the first set from the series of control subjects to the first set of nucleic acid sequences from the subjects;
wherein steps (e) to (h) are performed before, simultaneously with or after steps (a) to (c);
and wherein said step of identifying from the subject's transcriptome a nucleic acid sequence encoding at least one Complementarity Determining Region (CDR) of the variable strand is based on said step of comparing sets of abundantly expressed nucleic acid sequences from step (h).
34. The non-transitory computer program product of claim 31, wherein the first set of abundantly expressed nucleic acid sequences from the subject encodes one or a combination of antibody fragments selected from the group consisting of: an Fc portion of an antibody, a single chain variable fragment of an antibody (ScFv), an Fv portion of an antibody, an Fab fragment of an antibody, an F (ab')2 fragment of an antibody, an Fd fragment of an antibody, an IgG-like fragment of an antibody, a variable chain of an antibody, and a constant region of an antibody.
35. The non-transitory computer program product of claims 30-34, wherein the first set of abundantly expressed nucleic acid sequences from the subject encodes one or a combination of variable heavy and/or variable light chain portions of the antibody.
36. The non-transitory computer program product of any one of claims 30 to 35, wherein the screening step comprises screening nucleic acid sequences of antibody fragments encoding one or more B Cell Receptor (BCR) sequences, and the step of calculating a clonality score for an antibody is determined at least in part by the formula:
where Ci is the clone score of rearrangement i and N is the total number of rearrangements.
37. The non-transitory computer program product of claims 30-36, wherein the screening nucleic acid sequences encoding one or more antibody fragments in the transcriptome of a series of control subjects comprises performing FASTQ, MIXCR, and vdjools functions on the transcriptome data.
38. The non-transitory computer program product of claims 30-37, wherein the screening the transcriptome of the subject for nucleic acid sequences encoding one or more antibody fragments comprises performing an alignment of cloned sequences.
39. The non-transitory computer program product of claim 38, wherein the alignment of cloned sequences comprises performing an immunizing SEQ function.
40. The non-transitory computer program product of any one of claims 30 to 39, wherein the sample is a tissue sample from a subject having a hyperproliferative cellular disease.
41. The non-transitory computer program product of claims 30-40, wherein the sample is a cancer tissue selected from the following cancers: glioblastoma multiforme, low-grade gliomas, lung adenocarcinomas, lung squamous carcinomas, pancreatic adenocarcinomas and skin cancers.
42. An antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising:
heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2206; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2208; a heavy chain CDR3, said heavy chain CDR3 comprising the amino acid sequence shown in SEQ ID NO: 2210; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO 2216; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2218; and a light chain CDR3, the light chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO 2220;
a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO. 2226; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO. 2228; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 2230; a light chain CDR1, said light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2236; a light chain CDR2, said light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2238; and a light chain CDR3, said light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2240;
a heavy chain CDR1, said heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2246; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2248; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO 2250; a light chain CDR1, said light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO 2256; a light chain CDR2, said light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO 2258; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2260;
a heavy chain CDR1, said heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2266; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2268; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2270; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2276; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2278; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2280;
heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO. 2286; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO 2288; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO. 2290; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2296; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO 2298; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2300;
heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2306; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2308; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 2310; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2316; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2318; and a light chain CDR3, the light chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2320;
a heavy chain CDR1, said heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2326; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2328; a heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2330; a light chain CDR1, said light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2336; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2338; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2340;
a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence as set forth in SEQ ID NO: 2346; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence as set forth in SEQ ID NO: 2348; a heavy chain CDR3, the heavy chain CDR3 includes an amino acid sequence shown in SEQ ID NO. 2350; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2356; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2358; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2360;
heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2366; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2368; a heavy chain CDR3, said heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 2370; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2376; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2378; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2380;
heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2386; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2388; a heavy chain CDR3, said heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 2390; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2396; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2398; and a light chain CDR3, the light chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2400;
a heavy chain CDR1, said heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2406; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2408; a heavy chain CDR3, the heavy chain CDR3 comprises an amino acid sequence shown as SEQ ID NO: 2410; a light chain CDR1, said light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2416; a light chain CDR2, said light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2418; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO. 2420;
heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2426; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2428; a heavy chain CDR3, the heavy chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 2430; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2436; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2438; and a light chain CDR3, the light chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2440;
a heavy chain CDR1, the heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2446; a heavy chain CDR2, the heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2448; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2450; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2456; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2458; and a light chain CDR3, the light chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2460;
a heavy chain CDR1, the heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2466; a heavy chain CDR2, the heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2468; a heavy chain CDR3, the heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2470; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2476; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2478; and a light chain CDR3, the light chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2480;
a heavy chain CDR1, the heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2486; a heavy chain CDR2, the heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2488; a heavy chain CDR3, the heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2490; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2496; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2498; and a light chain CDR3, the light chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2500;
a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2506; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2508; a heavy chain CDR3, wherein the heavy chain CDR3 comprises an amino acid sequence shown as SEQ ID NO: 2510; a light chain CDR1, said light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2516; a light chain CDR2, said light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2518; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2520;
heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence as shown in SEQ ID NO: 2526; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence as shown in SEQ ID NO: 2528; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO. 2530; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2536; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2538; and a light chain CDR3, the light chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2540;
a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2546; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2548; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO. 2550; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2556; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2558; and a light chain CDR3, the light chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2560;
a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2566; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2568; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO. 2570; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2576; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2578; and a light chain CDR3, the light chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2580;
a heavy chain CDR1, said heavy chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2586; a heavy chain CDR2, said heavy chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2588; a heavy chain CDR3, said heavy chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO. 2590; a light chain CDR1, the light chain CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2596; a light chain CDR2, the light chain CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2598; and a light chain CDR3, said light chain CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 2600;
a heavy chain CDR1, said heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2606; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2608; a heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2610; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2616; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2618; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2620;
a heavy chain CDR1, said heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2626; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2628; a heavy chain CDR3, said heavy chain CDR3 comprising the amino acid sequence shown in SEQ ID NO: 2630; a light chain CDR1, the light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2636; a light chain CDR2, the light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2638; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2640;
heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2646; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2648; a heavy chain CDR3, said heavy chain CDR3 comprising the amino acid sequence shown in SEQ ID NO: 2650; a light chain CDR1, the light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2656; a light chain CDR2, the light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2658; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2660;
heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2666; a heavy chain CDR2, said heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2668; a heavy chain CDR3, said heavy chain CDR3 comprising the amino acid sequence shown in SEQ ID NO: 2670; a light chain CDR1, the light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2676; a light chain CDR2, the light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2678; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2680;
heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2686; heavy chain CDR2, said heavy chain CDR2 includes the amino acid sequence shown in SEQ ID NO: 2688; a heavy chain CDR3, said heavy chain CDR3 comprising the amino acid sequence shown in SEQ ID NO: 2690; a light chain CDR1, the light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2696; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2698; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 2700; and
heavy chain CDR1, said heavy chain CDR1 includes the amino acid sequence shown in SEQ ID NO: 2706; heavy chain CDR2, said heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 2708; a heavy chain CDR3, said heavy chain CDR3 includes the amino acid sequence shown in SEQ ID NO: 2710; a light chain CDR1, said light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2716; a light chain CDR2, said light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2718; and a light chain CDR3, the light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO 2720.
43. An antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising:
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID No. 2204 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID No. 2204, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID No. 2214 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID No. 2214;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2224 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2224, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2234 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2234;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2244 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2244, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2254 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2254;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2264 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2264, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2274 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2274;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2284 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2284, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2294 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2294;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2304 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2304, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2314 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2314;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2324 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2324, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2334 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2334;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2344 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2344, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2354 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2354;
a heavy chain variable domain comprising the amino acid sequence set forth as SEQ ID NO:2364 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2364, and/or a light chain variable domain comprising the amino acid sequence set forth as SEQ ID NO:2374 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2374;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2384 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2384, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2394 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2394;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2404 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2404, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2414 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2414;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2424 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2424, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2434 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2434;
a heavy chain variable domain comprising the amino acid sequence set forth as SEQ ID NO:2444 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2444, and/or a light chain variable domain comprising the amino acid sequence set forth as SEQ ID NO:2454 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2454;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2464 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2464, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2474 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2474;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2484 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2484, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2494 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2494;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2504 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2504, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2514 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2514;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2524 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2524, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2534 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2534;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2544 or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO. 2544, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2554 or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO. 2554;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2564 or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO. 2564, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2574 or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO. 2574;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2584 or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:2584, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2594 or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 2594;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2604 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2604, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2614 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2614;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2624 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2624, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2634 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2634;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2644 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2644, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2654 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2654;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2664 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2664, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2674 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2674;
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2684 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2684, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2694 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2694; and
a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2704 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2704, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2714 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2714.
44. An antibody or antigen-binding fragment thereof that binds to tumor tissue, comprising:
a heavy chain comprising the amino acid sequence shown as SEQ ID No. 2202 or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID No. 2202, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID No. 2212 or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID No. 2212;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2222 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2222, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2232 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2232;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2242 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2242, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2252 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2252;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2262 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2262, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2272 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2272;
a heavy chain comprising the amino acid sequence set forth as SEQ ID NO. 2282 or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO. 2282, and/or a light chain variable domain comprising the amino acid sequence set forth as SEQ ID NO. 2292 or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO. 2292;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2302 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2302, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO. 2312 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2312;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2322 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2322, and/or a light chain, said light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2332 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2332;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2342 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2342, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2352 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2352;
a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:2362 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2362, and/or a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:2372 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2372;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2382 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2382, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2392 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2392;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2402 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2402, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2412 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2412;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2422 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2422, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2432 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2432;
a heavy chain comprising the amino acid sequence set forth as SEQ ID NO:2442 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2442, and/or a light chain variable domain comprising the amino acid sequence set forth as SEQ ID NO:2452 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2452;
a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:2462 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2462, and/or a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:2472 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2472;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2482 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2482, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2492 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2492;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2502 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2502, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2512 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2512;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2522 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2522, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO:2532 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2532;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2542 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2542, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2552 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2552;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2562 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2562, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2572 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2572;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2582 or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO. 2582, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO. 2592 or a sequence at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO. 2592;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2602 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2602, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2612 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2612;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2622 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2622, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2632 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2632;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2642 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2642, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2652 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2652;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2662 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2662, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2672 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2672;
a heavy chain comprising the amino acid sequence shown as SEQ ID NO:2682 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2682, and/or a light chain variable domain comprising the amino acid sequence shown as SEQ ID NO:2692 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2692; and
a heavy chain comprising the amino acid sequence shown as SEQ ID NO. 2702 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2702, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO. 2712 or a sequence having at least 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO. 2712.
45. The antibody or antigen-binding fragment thereof that binds to tumor tissue according to claim 44, wherein
The heavy chain comprises an amino acid sequence shown as SEQ ID NO:2202, and the light chain comprises an amino acid sequence shown as SEQ ID NO: 2212;
the heavy chain comprises an amino acid sequence shown as SEQ ID NO. 2222, and the light chain comprises an amino acid sequence shown as SEQ ID NO. 2232;
the heavy chain comprises an amino acid sequence as shown in SEQ ID NO 2242 and the light chain comprises an amino acid sequence as shown in SEQ ID NO 2252;
the heavy chain comprises the amino acid sequence shown as SEQ ID NO:2262, and the light chain comprises the amino acid sequence shown as SEQ ID NO: 2272;
the heavy chain comprises the amino acid sequence shown as SEQ ID NO. 2282, and the light chain comprises the amino acid sequence shown as SEQ ID NO. 2292;
the heavy chain comprises the amino acid sequence shown as SEQ ID NO. 2302 and the light chain comprises the amino acid sequence shown as SEQ ID NO. 2312;
the heavy chain comprises an amino acid sequence shown as SEQ ID NO:2322, and the light chain comprises an amino acid sequence shown as SEQ ID NO: 2332;
the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO:2342 and the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 2352;
the heavy chain comprises the amino acid sequence shown as SEQ ID NO:2362, and the light chain comprises the amino acid sequence shown as SEQ ID NO: 2372;
the heavy chain comprises the amino acid sequence shown as SEQ ID NO:2382, and the light chain comprises the amino acid sequence shown as SEQ ID NO: 2392;
the heavy chain comprises an amino acid sequence shown as SEQ ID NO:2402, and the light chain comprises an amino acid sequence shown as SEQ ID NO: 2412;
the heavy chain comprises the amino acid sequence shown as SEQ ID NO:2422, and the light chain comprises the amino acid sequence shown as SEQ ID NO: 2432;
the heavy chain comprises an amino acid sequence shown as SEQ ID NO:2442, and the light chain comprises an amino acid sequence shown as SEQ ID NO: 2452;
the heavy chain comprises an amino acid sequence shown as SEQ ID NO:2462 and the light chain comprises an amino acid sequence shown as SEQ ID NO: 2472;
the heavy chain comprises an amino acid sequence shown as SEQ ID NO:2482 and the light chain comprises an amino acid sequence shown as SEQ ID NO: 2492;
the heavy chain comprises an amino acid sequence shown as SEQ ID NO:2502, and the light chain comprises an amino acid sequence shown as SEQ ID NO: 2512;
the heavy chain comprises an amino acid sequence shown as SEQ ID NO:2522, and the light chain comprises an amino acid sequence shown as SEQ ID NO: 2532;
the heavy chain comprises an amino acid sequence shown as SEQ ID NO. 2542, and the light chain comprises an amino acid sequence shown as SEQ ID NO. 2552;
the heavy chain comprises the amino acid sequence shown as SEQ ID NO. 2562, and the light chain comprises the amino acid sequence shown as SEQ ID NO. 2572;
the heavy chain comprises the amino acid sequence shown as SEQ ID NO. 2582, and the light chain comprises the amino acid sequence shown as SEQ ID NO. 2592;
the heavy chain comprises the amino acid sequence shown as SEQ ID NO:2602, and the light chain comprises the amino acid sequence shown as SEQ ID NO: 2612;
the heavy chain comprises the amino acid sequence shown as SEQ ID NO:2622 and the light chain comprises the amino acid sequence shown as SEQ ID NO: 2632;
the heavy chain comprises the amino acid sequence shown as SEQ ID NO:2642, and the light chain comprises the amino acid sequence shown as SEQ ID NO: 2652;
the heavy chain comprises the amino acid sequence shown as SEQ ID NO:2662, and the light chain comprises the amino acid sequence shown as SEQ ID NO: 2672;
the heavy chain comprises the amino acid sequence shown as SEQ ID NO:2682, and the light chain comprises the amino acid sequence shown as SEQ ID NO: 2692; or
The heavy chain comprises the amino acid sequence shown as SEQ ID NO 2702 and the light chain comprises the amino acid sequence shown as SEQ ID NO 2712.
46. The antibody or antigen-binding fragment thereof of any one of claims 42 to 45, wherein the fragment is selected from the group consisting of Fab, Fab ', F (ab')2, Fv, domain antibody, and single chain antibody.
47. The antibody or antigen-binding fragment thereof of any one of claims 42-46, wherein the antibody or antigen-binding fragment thereof is classified as an isotype selected from the group consisting of IgG, IgM, IgD, IgA, and IgE.
48. An antibody or antigen-binding fragment thereof that binds to tumor tissue, which competes with the antibody or antigen-binding portion thereof of any one of the preceding claims.
49. The antibody or antigen-binding fragment thereof of any one of claims 42 to 48, wherein the antibody or antigen-binding portion thereof is humanized.
50. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 42 to 49, and a pharmaceutically acceptable carrier.
51. The pharmaceutical composition of claim 50, which is lyophilized.
52. An isolated nucleic acid encoding the antibody or antigen-binding fragment thereof according to any one of claims 42 to 48.
53. A vector comprising the isolated nucleic acid of claim 52.
54. A host cell comprising the vector of claim 53.
55. The host cell of claim 54, wherein the host cell is a prokaryotic cell or a eukaryotic cell.
56. The host cell of claim 55, wherein the eukaryotic cell is a protoplast cell, an animal cell, a plant cell, a fungal cell, a yeast cell, a mammalian cell, an avian cell, or an insect cell.
57. The host cell of claim 56, wherein the mammalian cell is a CHO cell or a COS cell.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762575369P | 2017-10-20 | 2017-10-20 | |
US62/575369 | 2017-10-20 | ||
PCT/US2018/056774 WO2019079762A1 (en) | 2017-10-20 | 2018-10-19 | Methods of antibody discovery using transcriptomes and compositions derived therefrom |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111492066A true CN111492066A (en) | 2020-08-04 |
Family
ID=66173896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880082663.9A Pending CN111492066A (en) | 2017-10-20 | 2018-10-19 | Methods of antibody targeting using transcripts and compositions derived therefrom |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111492066A (en) |
WO (1) | WO2019079762A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020221463A1 (en) * | 2019-05-02 | 2020-11-05 | Ava Lifescience Gmbh | Method for selecting biological binding molecules |
JP7529690B2 (en) * | 2019-05-02 | 2024-08-06 | アー・ファウ・アー ライフサイエンス ゲー・エム・ベー・ハー | Biological binding molecules |
EP3733709A1 (en) * | 2019-05-02 | 2020-11-04 | AVA Lifescience | Biological binding molecules |
KR20230118573A (en) * | 2020-11-11 | 2023-08-11 | 에이치큐 한 | Bifunctional antagonists of activin/TGF-beta and RANKL and uses thereof |
US20240158478A1 (en) * | 2021-03-15 | 2024-05-16 | Emory University | SARS-CoV-2 Antibodies and Fragments, Therapeutic Uses, Diagnostic Uses, and Compositions Related Thereto |
WO2023034566A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Anti-dll3 antibodies and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105189779A (en) * | 2012-10-01 | 2015-12-23 | 适应生物技术公司 | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization |
US9234240B2 (en) * | 2010-05-07 | 2016-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Measurement and comparison of immune diversity by high-throughput sequencing |
US20160146830A1 (en) * | 2010-05-17 | 2016-05-26 | Board Of Regents, The University Of Texas System | Proteomic identification of antibodies |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160335542A1 (en) * | 2015-05-12 | 2016-11-17 | Dell Software, Inc. | Method And Apparatus To Perform Native Distributed Analytics Using Metadata Encoded Decision Engine In Real Time |
-
2018
- 2018-10-19 WO PCT/US2018/056774 patent/WO2019079762A1/en active Application Filing
- 2018-10-19 CN CN201880082663.9A patent/CN111492066A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9234240B2 (en) * | 2010-05-07 | 2016-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Measurement and comparison of immune diversity by high-throughput sequencing |
US20160146830A1 (en) * | 2010-05-17 | 2016-05-26 | Board Of Regents, The University Of Texas System | Proteomic identification of antibodies |
CN105189779A (en) * | 2012-10-01 | 2015-12-23 | 适应生物技术公司 | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization |
Non-Patent Citations (4)
Title |
---|
ALEXANDRE REUBEN等: "TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence" * |
DMITRIY A BOLOTIN等: "Antigen receptor repertoire profiling from RNA-seq data" * |
GIULIA PACIELLO等: "VDJSeq-Solver: in silico V(D)J recombination detection tool" * |
MICHAEL D IGLESIA等: "Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer" * |
Also Published As
Publication number | Publication date |
---|---|
WO2019079762A1 (en) | 2019-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210230269A1 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
US9469689B2 (en) | Therapeutic DLL4 binding proteins | |
US10662241B1 (en) | HER3 antigen-binding molecules | |
CN111492066A (en) | Methods of antibody targeting using transcripts and compositions derived therefrom | |
CN110407941B (en) | High affinity antibodies to CD39 and uses thereof | |
CA2687411A1 (en) | Humanized antibodies which bind to a.beta. (1-42) globulomer and uses thereof | |
KR20120089659A (en) | Therapeutic dll4 binding proteins | |
TW201134489A (en) | Basigin binding proteins | |
EP3964530A1 (en) | Anti-pd-1 and pd-l1 tetravalent bispecific antibody | |
WO2023143535A1 (en) | Antibody targeting il-18bp and use thereof | |
US20220135686A1 (en) | Antibody that binds to human pd-l1 | |
AU2022273136A1 (en) | Binding molecule against dll3 and use thereof | |
TW201139667A (en) | Amyloid-beta binding proteins | |
CA3206838A1 (en) | Pd-1 binding molecule and application thereof | |
JP2024509369A (en) | Anti-PD-L1 antibody and its use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200804 |
|
WD01 | Invention patent application deemed withdrawn after publication |